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Abstract 
Obesity is a public health concern and requires effective management with multiple 
approaches. Dietary supplements of bioactive compounds that can improve fatty acid 
oxidation and thermogenesis are currently in focus to develop anti-obese food 
ingredients/nutraceuticals without side-effects. Dietary 1,3-diacylglycerol (DAG) and 
sXSSOHPHQWDWLRQRIĮ-lipoic acid (LA) have been shown to reduce fat accumulation and 
improve lipid profile while phytosterols (PS) are known for reducing blood cholesterol.  
In this thesis, novel lipid derivatives of LA with PS and 1,3-DAG were synthesized 
based on the hypothesis, that they would possess advantages over the individual 
constituents in controlling obesity due to increased stability, solubility, and 
bioavailability. A mild esterification method was developed to synthesize conjugates of 
LA and its reduced form (DHLA), with PS and 1,3-DAG yielding 60-80% of the 
products. The novel DHLA derivatives showed higher in vitro free radical scavenging 
capacity than the corresponding LA derivatives, and were comparable to pure DHLA.  
In a pilot in vitro study, LA derivative with 1,3-dilaurin (diLaLA) was completely 
hydrolyzed by pancreatic lipase, releasing monolipoate, C12:0 and LA. Free LA was 
detected in plasma 2 h after oral administration of diLaLA to mice. Effects of diLaLA 
on body weight and lipid metabolism were evaluated in male C57BL/6J diet-induced 
obese mice on a high fat diet (HFD) and a control treated only with vehicle. After oral 
administration of diLaLA at 10, 50 and 250 mg/kg body wt. daily for 6 weeks, body 
weight was lowered (p<0.05) in high dose group compared with the control and low 
dose groups. Treatment with high dose also reduced (p<0.05) plasma and hepatic free 
fatty acid contents, while the concentrations of blood glucose, total cholesterol, and 
liver triacylglycerol showed a reducing trend compared with the control. Stearoyl-CoA 
desaturase (SCD)-1 activity, estimated by SCD16 index (C16:1n-7/C16:0), showed 
lower activity (p<0.05) in white adipose tissues while some key genes involved in fatty 
DFLGȕ-oxidation in liver showed upregulation in the high dose group compared with the 
control. Oral treatment with diLaLA reduced HFD-induced obesity in mice, possibly 
through enhanced energy expenditure via ȕ-oxidation and suppressing in vivo 
lipogenesis, suggesting its potential as a promising candidate against obesity.  
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1 Introduction 
Body weight is regulated by biological factors and remains relatively stable 
over time in many adults (Fried & Horenstein, 2011). A combination of 
genetic, environmental and behavioral factors influence accumulation of fat in 
the body, despite the neurobiological processes controlling the food intake 
(Haslam & James, 2005; Miller et al., 2011). In modern society, sedentary life 
style with over-consumption of diets rich in energy, promotes extra fat 
accumulation in the body leading to obesity. Body fat amount is measured 
indirectly using body mass index (BMI, weight in kg/height in m
2). Individuals 
with BMI between 25.0 and 29.9 kg/m
2 are considered overweight, while those 
with BMI above 30 kg/m
2 are categorized as obese (WHO).  
Obesity has increased around the world, particularly during the past three 
decades and it has reached epidemic levels. One out of two adults in OECD 
countries is overweight or obese (OECD Fact Book, 2013). Obesity is closely 
associated with dyslipidemia, glucose intolerance and hypertension, 
collectively known as metabolic syndrome, and is considered a major risk 
factor for cardiovascular diseases (CVD), type II diabetes mellitus (T2DM) and 
some types of cancer (Grundy et al., 2004; Haslam & James, 2005; Miller et 
al., 2011). In addition to the losses related to productivity and increased health 
care costs, it is also a concern of the quality of life of the affected individuals. 
Thus effective control measures are extremely important to overcome the 
problems of obesity. Reducing excess body weight, mainly by dietary 
modifications and exercise, is considered as the basic therapy for reducing fat 
accumulation. However, long term weight management is a challenging task 
for many obese individuals, resulting a transient phase of weight loss followed 
by a return to obesity (Dulloo, 2011; Ara et al., 2012). Therefore drug therapy 
is sometimes recommended, in combination with dietary modifications and 
exercise, for such individuals. However, long term use of such drugs can be 12 
limited due to their side-effects whereas some individuals may not respond to 
these drugs (Robinson & Niswender, 2009; Ara et al., 2012). 
Managing obesity by stimulating energy expenditure through thermogenesis 
and fatty acid oxidation is currently being examined in the pharmaceutical, 
nutraceutical and functional food research and industry (Yanagita & Nagao, 
2008; Dulloo, 2011). A wide array of natural bioactive food ingredients, such 
as polyphenols, proteins/amino acids, and lipids/fatty acids, are being 
investigated for their potential as thermogenic anti-obesity products. They may 
act on single or multiple targets, increasing energy expenditure and reducing 
obesity and related health risks. In the Western diet, about 35-40% of total 
energy intake is from fat (Rudowska et al., 2005). Thus lipid based bioactive 
ingredients can easily be enriched in foods without causing marked changes in 
eating habits and can be used as part of an integrated approach to reduce 
obesity.  
Some lipid based-bioactive ingredients such as phytosterols (PS) are known 
for their effect in reducing total cholesterol (T-Ch) and low density lipoprotein 
cholesterol (LDL-Ch), and have been used as functional foods for many years 
(AbuMweiss et al., 2008). Research has shown that long term substitution of 
more than 10% of the normal daily triacylglycerol (TAG) intake by 1,3-
diacylglycerol (DAG) can significantly reduce body weight and fat 
accumulation by increasing energy expenditure and thermogenesis, compared 
with a similar amount of ordinary TAG intake with same fatty acid 
composition (Rudowska et al., 2005; Yanai et al., 2007). Supplementation of 
Į-lipoic acid (LA) in doses of 800-1800 mg/d have shown multiple therapeutic 
properties including weight reducing effects through enhanced energy 
expenditure (Carbonelli et al., 2010; Koh et al., 2011).  
The bioavailability of a given bioactive compound often depends on its 
chemical and physical properties, including solubility and stability. Therefore 
novel derivatives of existing natural bioactive food compounds are being 
investigated to improve such properties in order to deliver enhanced effect 
(Meunier, 2007; Koufaki et al., 2009). The molecular structure of LA provides 
an ideal chemical entity that can easily be conjugated with other small 
bioactive molecules to form multifunctional derivatives (Koufaki et al., 2009). 
Such novel derivatives of LA with other bioactive molecules might provide 
combined or synergistic effects through their action on single or multiple 
targets, possibly providing innovative supplements that can increase energy 
expenditure and suppress fat accumulation, reducing the underlying causes of 
obesity. 13 
2 Background 
2.1 Obesity   
 
Obesity has increased steadily around the world, particularly since the 1980s, 
and is now becoming a common problem also in developing countries. Today, 
53% of adults in OECD countries are overweight and 18% of them are obese 
(Figure 1). The prevalence of obesity is highest in the USA and Mexico, where 
it occurs more than 30% of the population. In Denmark, Sweden and Norway, 
obesity has increased by 40% during the past decade. In Sweden, 13% of the 
population aged above 15 years was obese in 2010 (OECD Fact Book, 2013). 
According to predictions, there will be 2.3 billion over weight adults around 
the world by 2015 and 700 million of them will be categorized as obese 
(WHO). The OECD has also reported that obesity is responsible for 1-3% of 
total health expenditure in most OECD countries, whereas it accounts for 5-
10% in the USA (OECD Fact Book, 2013). When productivity related losses 
are added to the health care costs, obesity accounts for over 1% of gross 
domestic product (GDP) in the USA.  
Currently used BMI thresholds to define obesity do not measure the fat 
content accurately and tend to vary across gender, age and ethnicity. Therefore 
waist-to-hip ratio and waist-to-height ratio have been suggested as more 
precise indirect measurements of obesity (Browning et al., 2010; Ashwell et 
al., 2012). Recently, dual-energy X-ray absorptiometry (DEXA) emerged as a 
direct measure of total and regional body fat amount (De Lorenzo et al., 2011). 14 
 
Figure 1. Prevalence of obesity as a % of the population above 15 years age in some selected 
countries in 2010 (Source: OECD Fact Book, 2013). 
Obesity associated risk factor for CVD: Atherosclerosis 
 
CVD is the major cause of death, representing 30% of total death in the world 
(WHO). Atherosclerosis is the primary underlying cause for CVD. Obesity 
associated multiple risk factors such as dyslipidemia, hypertension, diabetes 
and oxidative stress induce atherosclerosis (Rossenfeld, 1989; Grundy et al., 
2004; Miller et al., 2011; WHO). The atherogenic impact of high concentration 
of blood cholesterol, particularly LDL-Ch, and low concentration of high 
density lipoprotein-cholesterol (HDL-Ch), is well established (Rossenfeld, 
1989; Miller et al., 2011; Ference et al., 2012). Therefore comprehensive 
action through integrated approaches are important to reduce above mentioned 
risk factors. Prolonged exposure to lower LDL-Ch beginning early in life, has 
been found to reduce the risk of CVD by 55%, compared with a statin 
treatment started later in the life, highlighting the importance of primary 
prevention strategies to maintain low LDL-Ch concentration (Ference et al., 
2012). 
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2.2 Lipid  metabolism   
2.2.1  Dietary lipids and metabolism 
 
Lipids are a group of heterogeneous hydrophobic organic molecules. They are 
mainly fatty acids (FA), their derivatives including mono-, di-, tri-
acylglycerols and phospholipids, as well as sterols such as cholesterol. Dietary 
lipids are essential for growth and development and serve as an energy reserve 
in the body. Major proportion of dietary lipids consists of TAG (Rudowska et 
al., 2005). 
Digestion of dietary lipids starts in the stomach and continues in the small 
intestine, where DAG and TAG are hydrolyzed by lipase into 
monoacylglycerols (MAG) and free fatty acids (FFA) and absorbed into the 
enterocytes. There they are re-esterified to TAG and incorporated into 
chylomicrons secreted into blood via lymph. Circulating lipids are associated 
with proteins and are known as lipoproteins, which contain non-polar lipids in 
the core facilitating their transport in the body (Harvey & Ferrier, 2011). 
Lipoproteins contain different amounts of phospholipids, TAG, cholesterol and 
cholesterol esters, and vary in density (Table 1). Other lipids in the body are 
mainly compartmentalized in membranes or stored as TAG in adipose tissues 
(AT).  
The liver functions as the major organ involved in lipid metabolism. In 
addition to FA from the diet, FAs are also synthesized in hepatocytes via fatty 
acyl-CoA from carbohydrate metabolism. Stearoyl-coenzyme A desaturase 
(SCD)-1, catalyzes the rate limiting step in biosynthesis of monounsaturated 
FA (MUFA), which is a major component in tissue lipids (Dobrzyn et al., 
2005; Flowers & Ntambi, 2008). The FA in the liver are re-esterified into TAG 
and used for the synthesis of very low density lipoproteins (VLDL). Surplus 
energy supplied from food is reserved as TAG stored in adipose tissues (AT). 
When FA are required by the body for energy, hormone-sensitive lipase 
hydrolyzes TAG in adipocytes and FFA are carried by serum albumin to the 
OLYHUDQGSHULSKHUDOWLVVXHVZKHUHHQHUJ\LVSURGXFHGYLDȕ-oxidation of FA. In 
healthy people the plasma FFA concentration remains relatively stable, as 
removal by peripheral tissues is replaced by lipolysis of subcutaneous AT. In 
the fasting state, almost all circulating FFA are derived from hydrolysis of 
subcutaneous AT and transported to peripheral tissues to be oxidized (Fried & 
Horenstein, 2011). 
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Table 1. Lipid composition of lipoprotein classes and some of their physical properties 
Parameter CM  VLDL  LDL  HDL 
Total lipid (%)*  99  91  80  44 
Triacylglycerol (%)  85  55  10  6 
Cholesterol esters (%)  3  18  50  40 
Cholesterol (%)  2  7  11  7 
Phospholipids (%)  8  20  29  46 
      Density (g/mL)  <0.94  0.94-1.006  1.006-1.063  1.063-1.210 
      Diameter (Å)  6000-2000  600  250  70-120 
Abbreviations: CM, chylomicrons; VLDL, very low density lipoproteins; LDL, low density 
lipoproteins; HDL, high density lipoproteins; *, based on wt./wt. and  remaining materials are 
apoproteins (Source: The AOCS Lipid Library, 2013). 
 
2.2.2  Implications of obesity on lipid metabolism  
 
Obesity is the most common disorder in energy homeostasis, evident as extra 
fat accumulation (Fried & Horenstein, 2011). During the initial stages of 
weight gain, the size of adipocytes increases by up to 2-3 times the normal 
volume, facilitating storage of TAG. With prolonged over-nutrition and excess 
energy, pre-adipocytes are stimulated and differentiated into mature fat cells, 
increasing the number of adipocytes and further expanding the fat storage 
(Fried & Horenstein, 2011).  
The adipocyte mass is known as a major endocrine organ and plays a 
pivotal role in the regulation of body weight and lipid metabolism. In healthy 
people, one of the adipocyte-derived hormones, leptin, regulates food intake 
(FI) and body weight. However, changes in molecular signals originating from 
the increased adipocyte mass in obese individuals are believed to cause some 
dysfunctions in intracellular lipid metabolism and exceed the normal regulation 
by leptin (Dobrzyn et al., 2005; Fried & Horenstein, 2011). In addition, excess 
fat mass has been shown to produce extra amounts of pro-inflammatory 
cytokines. In contrast to other cytokines, the concentration of adiponectin, 
which stimulate energy expenditure through FFA oxidation and glycemic 
control in peripheral tissues, has been found to be reduced in obese individuals 
(Ukkola & Santaniemi, 2002). Moreover, visceral AT shows a high rate of 
lipolysis, resulting in high influx of FFA to the liver in obese individuals 
(Ukkola & Santaniemi, 2002; Cornier et al., 2008).  
In adults, with increasing BMI and total body fat content (TBF%), the 
concentrations of different plasma lipid components such as T-Ch, LDL-Ch 
and TAG are increased showing a positive correlation whereas the 
concentration of HDL-Ch is decreased (Table 2). The contribution of obesity to 17 
serum lipid concentrations is particularly evident when BMI is above 30 or 
TBF% is very high (Brown et al., 2000; Choi et al., 2003).  
Table 2. Serum lipid concentrations based on body mass index (BMI) and total body fat (TBF)  
Parameter  No. of cases 
(n) 
Serum lipid concentration (mean±SD, mg/dL) 
T-Ch TAG  HDL-Ch  LDL-Ch 
BMI (kg/m
2)       
Males       
 <18.5  49  191±38  99±32  53±11  119±33 
 18.5-22.9  428  200±36  135±57  46±10  129±31 
  23.0  307  211±35  193±96  43±8  124±33 
Females       
 <18.5  51  183±26  86±37  56±12  108±19 
 18.5-22.9  403  199±33  114±69  52±11  124±28 
  23.0  291  221±42  141±59  47±10  145±28 
TBF (%)       
Males       
 <12.0  50  173±24  87±38  50±12  108±22 
 12.0-21.9  481  204±35  142±71  45±11  128±34 
  22.0  253  218±37  199±73  41±9  130±37 
Females       
 <20.0  62  176±19  98±38  53±14  106±19 
 20.0-30.9  389  199±37  113±56  52±12  124±34 
  31.0  294  221±35  139±58  47±9  148±36 
Abbreviations: SD, standard deviation; T-Ch, total cholesterol; TAG, triacylglycerol; HDL-Ch, high density 
lipoprotein cholesterol; LDL-Ch, low density lipoprotein cholesterol (Choi et al., 2003). 
2.3  Clinical markers of lipid metabolism 
2.3.1 Cholesterol   
 
Cholesterol is a steroid alcohol categorized under lipids. About 75-80% of the 
circulating cholesterol is synthesized in the body, whereas the rest can be of 
different origin, such as dietary cholesterol (Fried & Horenstein, 2011). Apart 
from genetic reasons, obesity is the main factor affecting blood cholesterol 
content. Diets rich in saturated fatty acids (SFA) and trans-FA also increase the 
blood cholesterol (Rossenfeld, 1989; Miller et al., 2011). 
Age-adjusted serum T-Ch concentration above 200 mg/dL (5.2 mmol/L) is 
considered as a risk factor for CVD (Table 3), and it has been shown that the 
relative risk increases progressively with increasing cholesterol concentration 18 
(Miller et al., 2011). In general, LDL-Ch represents about 60-75% of T-Ch in 
serum (Rossenfeld, 1989). Therefore the link between atherogenic effect and 
serum T-Ch is mainly due to LDL-Ch. In addition, HDL-Ch concentration 
below 40 mg/dL is specified as a low amount, whereas a concentration above 
60 mg/dL is considered highly desirable (ATP III Guidelines, NCEP, 2001). 
The ratio of T-Ch to HDL-Ch has been suggested as a more robust and precise 
lipid measurement to estimate the obesity related CVD risk. When, the ratio of 
T-Ch to HDL-Ch is above 4.5, it is known as dyslipidemia, which clearly 
increases with increasing BMI (Brown et al., 2000). 
Table 3. Classification of serum concentrations of triacylglycerol, total cholesterol and LDL-
cholesterol (mg/dL) as risk factors for CVD events 
Designate Triacylglycerol  Total  cholesterol  LDL-Cholesterol 
Desirable  <150 <200 <100 
Borderline-high 150-199 200-239 130-159* 
High 200-499   240  160-189 
Very high  >500     190 
Abbreviations: CVD, cardio vascular disease; LDL, Low density lipoprotein; *, LDL-Ch concentration of 100-
129 mg/dL is classified as near optimal/above optimal. Source: ATP III Guidelines, NCEP (2001). 
 
2.3.2 Triacylglycerol   
 
Chylomicrons and VLDL are the main TAG-rich lipoproteins in blood, 
carrying approx. 85% and 55% (wt./wt.) TAG, respectively (Table 1). High 
TAG concentrations in blood can be due to increased synthesis and/or 
decreased catabolism of TAG-rich lipoproteins. According to current 
designations by NCEP, ATP III Guidelines (2001), a TAG concentration above 
150 mg/dL in the blood after 12 h of fasting is considered a risk factor in 
metabolic syndrome (Table 3). In general, high concentration of TAG is 
associated with obesity and is considered as a biomarker for visceral adiposity, 
insulin resistance and T2DM (Miller et al., 2011). 
Diets rich in fat generally result in elevated postprandial TAG 
concentration. Incorporation of dietary fatty acids (FA) into chylomicrons 
during chylomicron synthesis in small intestine depends on chain length and 
structure (saturation) of FA, and type of TAG or DAG. In contrast, diets rich in 
carbohydrates, but containing less fat result in lower TAG concentration in the 
postprandial state, but lead to a higher concentration in the fasting state 
(Lambert & Parks, 2012). After a carbohydrate-rich meal, de novo FA 
synthesis in the liver is followed by TAG and VLDL synthesis, thus increasing 
the TAG concentration in the fasting state. Borderline-high and high TAG 19 
concentrations are correlated with atherogenic lipoprotein remnants such as 
LDL which is a metabolite of VLDL (Miller et al., 2011). 
2.3.3   Free fatty acids  
 
Expanding visceral fat mass during abdominal obesity releases increasing 
amounts of FFA, which enter the portal vein and are directed to the liver. At 
the same time, it has been reported that obesity reduces the concentration of 
adiponectin derived from AT. As a result, obese individuals have lower 
clearance of FFA, leading to a chronically elevated circulating FFA 
concentration (Ukkola & Santaniemi, 2002; Fried & Horenstein, 2011).   
 
 
Figure 2. Potential mechanisms induced by enhanced plasma free fatty acid concentration during 
obesity resulting in diabetes, hypertension and vascular diseases. Abbreviations: Glut, glucose 
transport protein; NAD(P)H, nicotinamide adenine dinucleotide phosphate; NOS, nitric oxide 
synthase; NO, nitric oxide; ROS, reactive oxygen species (modified after Boden, 2008). 
Once FFA concentration in blood is elevated, it can inhibit the anti-lipolytic 
action of insulin, further increasing the rate of FFA release. Thus with 
prolonged obesity, elevated concentrations of FFA reduce insulin-stimulated 
glucose uptake in skeletal muscles, leading to insulin resistance (Figure 2). 
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Increased amounts of FFA have been reported to cause accumulation of fatty 
acyl-CoA and activate serine/threonine kinase, which can interrupt insulin 
signaling by decreasing tyrosine phosphorylation of insulin receptor substrate 
(IRS)1/2. Consequently, this interferes with glucose transport protein (Glut 4), 
reducing glucose uptake in muscles and leading to an increase in hepatic 
glucose production. Moreover, elevated FFA is believed to induce production 
of protein kinase which has been reported to activate nicotinamide adenine 
dinucleotide phosphate (NADP)-oxidase and thereby produce reactive oxygen 
species (ROS). These ROS can destroy nitric oxide and affect vasodilatation 
leading to hypertension. In addition, elevated FFA promotes production of 
inflammatory and pro-atherogenic cytokines, which can impair endothelial 
function, causing a low grade of chronic inflammatory condition possibly 
leading to atherosclerosis (Ukkola & Santaniemi, 2002; Boden, 2008).  
High influx of portal FFA from abdominal AT is captured in the liver and 
re-esterified into TAG, which could eventually increase the amount of VLDL 
synthesized in the liver (Fried & Horenstein, 2011; Karpe et al., 2011; Miller et 
al., 2011). Considering its influence in energy metabolism, serum FFA 
concentration has been suggested as a biomarker for metabolic diseases such as 
T2DM and CVD (Azzazy et al., 2006; Karpe et al., 2011). Moreover, elevated 
plasma FFA concentration can cause an accumulation of TAG, known as 
ectopic fat deposition, in peripheral tissues other than AT such as muscle and 
liver tissues, due to insulin resistance (Boden, 2008; Karpe et al., 2011). 
 
2.3.4 Oxidative  stress   
 
Oxidative stress in biological systems can occur when free radical production 
exceeds the capacity of cellular antioxidant defense mechanisms, possibly due 
to diminished antioxidant levels (Packer et al., 1995; Biewenga et al., 1997; 
Rochette et al., 2013). An inverse correlation between antioxidant levels and 
central adiposity has been observed in obese individuals. Thus oxidative stress 
has been suggested as a biomarker for metabolic syndrome. (Higdon & Frei 
2003; Keany et al., 2003). As mentioned earlier, increasing fat mass in obese 
individuals has been shown to increase expression of pro-inflammatory 
cytokines, which may promote oxidative stress during obesity and trigger pro-
oxidative and pro-inflammatory processes causing endothelial dysfunction and 
progression of atherosclerosis, CVD and T2DM (Ukkola & Santaniemi, 2002; 
Boden, 2008).  
LDL-Ch is oxidized by free radicals during oxidative stress conditions 
causing chemical modifications. Furthermore, the endothelial wall becomes 21 
vulnerable to injuries during oxidative stress conditions and attracts 
monocytes, which may adhere to the endothelium. When the LDL-Ch 
concentration increases while oxidative defense mechanism is suppressed, this 
can trigger the atherosclerosis (Rossenfeld, 1989; Keany et al., 2003; Harvey 
& Ferrier, 2011). Thus chronic oxidative stress has been suggested as one of 
the mechanistic links between obesity and related chronic progressive 
pathological conditions (Higdon & Frei 2003; Keany et al., 2003; Boden, 
2008).  
2.4  Management of obesity by body weight reduction  
  
The primary aim in the management of obesity is to reduce excess body weight 
or fat accumulation in order to improve health. The first approach to achieve 
this objective is usually through healthy diet and regular physical activity (Ara 
et al., 2012). The effect of weight reduction is positively correlated with serum 
lipid concentration. According to meta-analyses, reducing body weight by 5-
10% can decrease serum TAG by 20%, T-Ch by 5-10% and LDL-Ch by 15%, 
while it can increase HDL-Ch by 8-10% (Miller et al., 2011; Ara et al., 2012).  
A reduction in body weight of 10 kg is reported to reduce T-Ch in humans by 
5% (0.23 mmol/L) (Poobalan et al., 2004). It has also been shown that a weight 
loss by approx.10% can reduce the risk of developing T2DM by 30-40%, while 
obesity related cancer deaths may be reduced by 40-50% (Ara et al., 2012; 
Rodgers & Collin, 2012). 
Unlike short-term weight reduction, maintenance of the reduced weight in 
long term has shown limited success in many obese people. In general, 
multiple regulatory methods are recommended for a better weight reducing 
effect through additive, complementary and synergistic effects. This kind of 
approach is particularly beneficial for individuals who have difficulties in 
achieving and maintaining satisfactory weight loss through basic strategies 
such as diet and exercise (Robinson & Niswender, 2009). In such cases a 
suitable drug therapy is introduced, in combination with modified diets and 
physical exercise. Though several approved weight reducing drugs are 
available, long term use of such drugs is limited due to their side-effects. 
Moreover, some individuals do not respond to such drugs (Ara et al., 2012). In 
severe cases of obesity (BMI above 40), bariatric surgery may be 
recommended (Ara et al., 2012).  
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2.5  Bioactive compounds against obesity and 
hypercholesterolemia  
 
Dietary supplements which can improve energy and lipid metabolism could be 
an important element in an integrated approach for long term control of obesity 
and associated risk factors.  Health promoting compounds isolated from food 
that are available in medicinal form and have shown to exert some 
physiological benefits, beyond basic nutritional requirements and reduce the 
risk of chronic disease are known as nutraceuticals (Moreau, 2004; Palthur et 
al., 2010). Such compounds can be added back to the foods, making them 
“functional foods” which are similar in appearance to conventional foods. 
There is growing interest in research and development of thermogenic and “fat-
burning” nutraceuticals or functional foods to increase energy expenditure and 
oxidation of fat (Yanagita & Nagao, 2008; Dulloo, 2011). Being natural 
components in foods, they might have an advantage over the adverse effects 
associated with existing weight reducing drugs (Dulloo, 2011). Dietary 
supplementation and/or substitution of traditional lipids in the diet with 
functional lipids, can be used as a tool, in combination with other approaches 
to manage obesity and related health risks (Yanagita & Nagao, 2008).  
 
2.5.1 Phytosterols 
 
Phytosterols (PS) are closely similar to cholesterol in chemical structure, but 
are synthesized only in plants (Figure 3). Among a large number of different 
PS present in foods, sitosterol is the most common (56-79%), followed by 
campesterol and stigmasterol. Brassicasterol occurs in foods from 
Brassicaceae family such as rapeseed oil. The major structural difference 
between these PS is based on their side chain and the presence of double bonds 
in the side chain. Saturated PS are known as phytostanols. In foods, PS mainly 
occur as free sterols, but they may also occur as sterol esters (Figure 4), 
glycosides or acylated glycosides. In general PS intake from non-enriched 
foods may vary from 140-360 mg/d. Cereal products, margarine, vegetable 
oils, fruits and vegetables are the main sources of dietary PS. Sitostanols are 
available in trace amounts except in cereals, which contain substantial amounts 
(Piironen & Lampi, 2004). 
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Figure 3. Molecular structure of cholesterol and some common phytosterols, naturally occuring in 
foods. 
Cholesterol-reducing effect of PS  
 
The cholesterol-reducing effect of PS was first reported in the 1950´s (Pollak, 
1953). Preparations of solid crystalline sitosterol were used in amounts up to 
25 g/d in early studies due to their very low solubility and bioavailability. 
Esterified PS with FA (Figure 4) was first reported to increase the 
bioavailability in 1994, with dietary intake of 1g PS/d lowering serum T-Ch by 
3.4% and LDL-Ch by 5.9% (Miettinen & Vanhanen, 1994). Consumption of 
approx. 2 g PS/d (3.3 g PS esters/d) can lower serum T-Ch by 6-10% and LDL-
Ch by 8-13% (Plat & Mensink, 2005; AbuMweiss et al., 2008; Demonty et al., 
2009). Nowadays commercial food products enriched with FA esters of PS are 
common on the market. Margarine products under the names of Benecol® and 
Becel pro.active® are some of the PS enriched margarines available in 
Sweden. Derivatives of PS with other bioactive compounds such as ferulic acid 
or ascorbic acid have been synthesized for potential additive functional 
properties (Condo et al., 2001; Jia et al., 2006). The functional properties of 
added PS are recommended for adults with high serum cholesterol 
concentrations.  
Possible mechanism of action 
 
The exact mechanism behind the cholesterol lowering effect of PS is not fully 
understood yet, and several mechanisms have been suggested. It is believed 
Cholesterol
Sitosterol HO
Campesterol Stigmasterol
HO
HO HO24 
that PS decrease cholesterol absorption in the small intestines (Plat & Mensink, 
2005; Harding et al., 2010; Davidson, 2011). About 50% of dietary cholesterol 
is absorbed in free form. Dietary cholesterol esters require prior hydrolysis by 
cholesterol esterase. In the intestinal lumen, cholesterol molecules are included 
in micelles with bile salts. PS are more hydrophobic and show higher affinity 
to micelles compared with cholesterol, thereby reducing incorporation of 
cholesterol in micelles.  
A single dose of PS/d has been shown to be effective, suggesting that the 
effects of PS remain in the intestines for a while and inducing its effects 
through some other mechanisms as well (Plat & Mensink, 2005). Several 
mechanisms by which PS may induce expression of genes involved in transport 
proteins, increasing the efflux of cholesterol and PS back into the intestinal 
lumen for excretion, have been suggested (Harding et al., 2010; Davidson, 
2011). 
 
Figure 4. Structures of naturally occuring sitosterol esters; e.g. 1, sitosterol ester of any fatty acid 
(R-COOH); 2, sitosterol ester with ferulic acid. 
2.5.2 1,3-Diacylglycerols 
 
TAG is the primary component (approx. 95-99%), in ordinary fats and 
vegetable oils (Yasukawa & Katsuragi, 2008). In the TAG molecule there are 
three FA esterified at each -sn position on the glycerol backbone, whereas in 
DAG only two -sn positions are esterified with FA (Figure 5). As a result, 
DAG may occur naturally in three different forms depending on the esterified 
position in the glycerol backbone, i.e., 1,2-DAG, 1,3-DAG or 2,3-DAG. In 
ordinary vegetable oils, DAG is available in amounts ranging from 1.0-9.5% 
depending on plant species. During fat digestion by pancreatic lipase, TAG is 
mainly hydrolyzed into 2-monoacylglycerol (MAG) and corresponding FFA. 
However, most of the 1,3-DAG is hydrolyzed into the corresponding FFA and 
sn-1- or sn-3-MAG due to preferential hydrolysis of pancreatic lipase at the sn-
H
12
R
CH3
O
O O
O
O
O25 
1 and sn-3 positions. Nevertheless, the energy value and absorption coefficient 
of DAG and TAG are similar (Yasukawa & Katsuragi, 2008).  
 
Figure 5. Chemical structure of triacylglycerol and diacylglycerols, where R1, R2 and R3 
represent fatty acids of different chain lengths and double bonds, esterified in a glycerol molecule. 
Anti-obesity effect of 1,3-diacyglycerol  
 
A number of studies in rodents and humans have collectively revealed that 
long-term substitution of TAG by 1,3-DAG above 10% of the normal daily 
TAG intake can significantly reduce body weight and fat accumulation 
compared with similar intake of TAG with same fatty acid composition (Maki 
et al., 2002; Murase et al., 2002; Rudowska et al., 2005; Yanai et al., 2010). In 
addition, decrease in postprandial serum TAG has been reported in number of 
studies with human subjects when more than 50% of the total TAG intake was 
replaced by 1,3-DAG (Rudowska et al., 2005; Tada, 2008). Toxicological 
studies on rats have not indicated any deleterious effects specific to DAG 
intake up to 2500 mg/kg body wt./d doses, while humans were reported to well 
tolerate doses high as 45 g/kg body wt./d (Borzelleca et al., 2008). Dietary 1,3-
DAG is considered under generally recognized as safe (GRAS) food substance 
in the USA, since 1,3-DAG is present in measurable quantities in common 
foods (Empie, 2008).  
Possible mechanism of action 
 
According to studies cited above, 1,3-DAG mediated effects can be due to 
metabolic differences related to its molecular structure compared with that of 
the TAG molecule (Rudowska et al., 2005; Yanai et al., 2007; Yasukawa & 
Katsuragi, 2008). Although the exact mechanism is not fully known yet, 26 
several possible pathways have been suggested. One suggestion is that 
digestion products of 1,3-DAG i.e., sn-1- or sn-3-MAG are poorly re-esterified 
into TAG after absorption into enterocytes and slow down subsequent 
synthesis of chylomicrons compared with 2-MAG from TAG digestion (Figure 
6). The MAG- and DAG-acyltransferase enzymes primarily involved in re-
synthesis of TAG, use 2-MAG as their substrate during TAG synthesis. This is 
known as the 2-MAG pathway. Since 1- or 3-MAG cannot be used as a 
substrate by 2-MAG acyltransferase, they are suggested to be re-esterified via 
the less active glycerol-3-phosphate pathway, which requires further break 
down of 1- or 3-MAG into glycerol and FFA (Yanai et al., 2007). This extra 
step may demand more energy and it was evidenced by enhanced expression of 
uncoupling protein (UCP)-2 and thermogenesis in the small intestines of 1,3-
DAG fed C57 BL/6J mice (Murase et al., 2002; Rudowska et al., 2005). 
 
 
Figure 6. Pathways showing the suggested differences between 1,3-diacylglycerol (DAG) and 
triacylglycerol (TAG) during digestion, absorption and re-esterification into TAG in the small 
intestine; Abbreviations: FFA, free fatty acids (modified after Yanai et al., 2007). 
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In addition, less efficient chylomicron synthesis may promote transport of 
more FFA to the liver, IDFLOLWDWLQJ HQKDQFHG ȕ-oxidation and energy 
expenditure rather than accumulation in adipose tissues (Murase et al., 2002; 
Rudowska, 2005; Hibi et al., 2008). The C57 BL/6J mice fed with 4% 1,3-
DAG in a 14% fat containing diet, showed up regulation of enzymes involved 
LQ ȕ-oxidation such as acyl-CoA oxidase and medium-chain acyl-CoA 
dehydrogenase, in small intestine (Murase et al., 2002). A recent study using 
Caco-2 cells revealed that 1-MAG, the final digestion product of 1,3-TAG, 
might induce serotonin receptors and increase plasma serotonin concentration 
resulting in XSUHJXODWLRQRIJHQHVLQYROYHGLQ)$ȕ-oxidation, FA metabolism 
and thermogenesis (Yanai et al., 2010). A higher respiratory quotient was 
observed in healthy individuals fed with 50% dietary 1,3-DAG replacing TAG 
compared with the control on 100% TAG (Hibi et al., 2008). 
 
2.5.3  Į-Lipoic acid 
 
Naturally occurring Į-LA is a bioactive compound also known as 1,2-
dithiolane-3-pentanoic acid or 6,8-thiotic acid (Figure 7). It is synthesized in 
mitochondria, where lipoamide is used as an essential cofactor in Į-ketoacid 
dehydrogenase complex, catalyzing oxidative decarboxylation during energy 
metabolism (Packer et al., 1995). In dietary sources, LA occurs as a lysine 
residue known as lipoyllysine. The most abundant sources of LA are spinach, 
broccoli, kidney, heart and liver which contain 0.9-3.2 g/g dry weight 
(Biewenga et al., 1997; Rochette et al., 2013). LA was isolated and chemically 
identified for the first time by Lester Reed and co-workers in 1951 (Packer et 
al., 1995). Chemically, it is derived from octanoic acid (C8:0) and consists of a 
terminal carboxylic acid and a dithiolane ring where the C6 and C8 carbons are 
connected with a disulfide bond.  
Due to its chiral center at C6, LA can exist as isomers of R-(+) or S-(-) 
forms. Therefore, a racemic mixture of synthetic LA contains both isomers in 
equal proportions. It has been reported that, 20-40% of a racemic LA mixture 
can be absorbed in humans, whereas R-(+)-LA has shown 40-50% higher 
plasma concentration compared with the S-(-) form (Teichert & Preiss, 2008; 
Packer & Cadenas, 2011). In addition, after absorption S-(-)-LA has shown 28 
fold slower reducing capacity into DHLA, compared with R-(+)-LA. Therefore 
the naturally available R-(+) form is considered more appropriate in oral 
supplements. Pure R-(+)-LA is less stable than racemic LA and tend to 
polymerize (Carlson et al., 2007). 
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Figure 7. Chemical structures, showing reduction of disulfide bond into thiol groups in Į-lipoic 
acid. 1) Į-lipoic acid; 2) dihydrolipoic acid. 
Health benefits of Į-lipoic acid 
 
In addition to its well established use as a pharmacotherapy in diabetes, today 
LA has become a common supplement or nutraceutical (Shay et al., 2009). 
Supplementation with free, exogenous LA in doses higher than obtained 
naturally from foods (200-600 mg/d) has been shown to have multiple 
therapeutic properties against diabetes, chronic inflammatory diseases, 
hypertension, vascular diseases and oxidative stress (Shay et al., 2009; 
Rochette et al., 2013), whereas doses of 800-1800 mg/d have demonstrated a 
significant weight reduction in human studies (Carbonelli et al, 2010; Koh et 
al., 2011). Oral supplementation with LA 800 mg/d to pre-obese and obese 
individuals for 4 months resulted in an 8% reduction in body weight in the pre-
obese group and a 9% reduction in the obese group (Carbonelli et al., 2010). 
 
Figure 8. Metabolites RIĮ-lipoic acid formed via ȕ-oxidation and S-methylation in the liver. The 
compounds shown are: 1), bisnorlipoic acid; 2), tetranor lipoic acid; 3), 2,4-
bis(methylthio)butanoic acid observed in human plasma and urine (modified after Teichert & 
Preiss, 2008). 
Orally supplemented free LA is absorbed showing approx. 30 min. of 
plasma half-OLIH7KHQLWLVH[WHQVLYHO\PHWDEROL]HGE\ȕ-oxidation in the liver, 
resulting in bisnor LA, tetranor LA and 2,4-bis(methylthio)butanoic acid 
(Figure 8), which are excreted rapidly through urine (Teichert & Preiss, 2008). 
LA given to Sprague Dawley rats in doses of 180 mg/kg body wt./d for 2 years 
did not show any adverse effects (Cremer et al., 2006). In humans, 
supplementation of 1800 mg/d did not cause any adverse effects, but a few 
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individuals reported an itching sensation (Koh et al., 2011). There is no 
agreement on the upper limit or recommended dose of LA for human use. 
 
Possible mechanism of action 
 
The exact mechanism behind the multiple biological effects of LA 
supplementation is not clearly understood yet. After absorption in the body, LA 
is reduced to dihydrolipoic acid (DHLA) by lipoamide dehydrogenase (Figure 
7). The LA and DHLA redox couple can function very efficiently as a 
biological antioxidant due to their high reduction potential (-320 mV). In vitro 
studies have shown that LA and DHLA can scavenge peroxinitrite, various 
ROS such as hydroxyl radicals, hypochlorus acid and hypochlorite. LA can 
also terminate singlet oxygen and chelate metal ions. In addition, DHLA can 
regenerate vitamin C and E, endogenous thiols such as intracellular glutathione 
(GSH), and cysteine involved in physiological redox systems (Biewenga et al., 
1997). Furthermore, recent research has shown that R-(+)-LA can increase 
GSH concentration by inducing GSH synthesis through antioxidant response 
element (ARE) mediated gene transcription regulated by nuclear factor Nrf2 
levels, which respond to oxidative stress (Shay et al., 2009; Packer & Cadenas, 
2011).  
Alhough LA is metabolized and rapidly cleared from the body, perceived 
effects observed during the post-administration period suggest that LA and 
DHLA stimulate neuro-hormonal functions in target cells and indirectly 
influence multiple cell signaling pathways in peripheral tissues (Shay et al., 
2009). Dietary supplementation with LA 0.1-0.5% (wt./wt.) has been found to 
improve blood lipid profiles by reducing FFA, TAG, T-Ch and LDL-Ch 
concentrations, whereas it increased HDL-Ch concentration in plasma and liver 
in rodents (Kim et al., 2004; Yang et al., 2008; Park et al., 2008). LA has been 
reported to downregulate expression of genes involved in the biosynthesis of 
cholesterol (Yang et al., 2008). 
LA can induce expression of genes such as acyl-CoA dehydrogenase, acyl-
CoA oxidase, hydroxyacyl-CoA dehydrogenase and carnitine 
palmitoyltransferase (CPT)-Į involved in oxidation of FA in the liver. Oral 
supplementation with LA enhanced adenosine monophosphate dependent 
protein kinase (AMPK) activity and increased glucose uptake and FA 
oxidation in peripheral tissues whereas it suppressed hypothalamic AMPK and 
reduced the food intake in rodents (Kim et al., 2004; Koh et al., 2008; Wang et 
al., 2010). It has been shown that up regulation of AMPK induced the 
phosphorylation of insulin receptor protein (IRS). Moreover, R-(+)-LA has 30 
been reported to increase the abundance of glucose transport proteins GLUT1 
and GLUT4, promoting glucose uptake (Shay et al., 2009; Wang et al., 2010; 
Packer & Cadenas, 2011). 
 
2.5.4 Derivatives  of  Į-lipoic acid 
 
The molecular structure of LA is considered an ideal chemical entity which can 
be covalently bound with other bioactive compounds (Koufaki et al., 2009). 
LA conjugated with another small molecule is known as a hybrid molecule 
when the two molecules represent two chemical entities and possess different 
biological functions. Thus the two molecules may interact with a single target 
or two or more independent/related targets (Meunier, 2007).  
Hybrid molecules of LA and trolox (a water soluble form of vitamin E) 
showed higher antioxidant activity against lipid peroxidation on rat liver 
microsomal membranes compared to pure LA or trolox (Koufaki et al., 2009). 
A phenolic compound, hydroxytyrasol esterified with LA, was found to exert 
antiproliferative effect on human colon cancer HT-29 cells (Bernini et al., 
2011). A derivative of PS linked with LA via POCl3 has been described by 
Milanova et al. (2001). According to our knowledge, there is no published data 
on any in vitro or in vivo study to evaluate potential biological effects of this 
PS derivative.  Derivatives of LA with different amides have been synthesized 
for multiple aspects such as neuroprotective and anti-inflammatory properties 
and have shown higher activity when tested using in vitro models (Sen et al., 
1998; Koufaki et al., 2009; Melagraki et al., 2009). Innovative novel 
supplements which can deliver a higher biological effect by using existing 
natural bioactive food components may be useful in an integrated approach to 
manage obesity and associated health risks. 
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3 Objectives 
The overall aims of this thesis were to, i) synthesize novel lipid derivatives of 
Į-lipoic acid (LA) based on the hypothesis that these conjugates would possess 
advantages over the individual compounds due to their increased solubility, 
stability and bioavailability,  ii) investigate the potential effects of one LA 
derivative with 1,3-diacylglycerol (1,3-dilauroyl-2-lipoyl-sn-glycerol; diLaLA) 
against high fat diet-induced obesity. Specific objectives were to;  
 
1)  Synthesize two series of novel LA derivatives with phytosterol (PS) 
and 1,3-diacylglcerol (DAG).  
 
2)  Characterize novel lipid conjugates by RP-HPLC-MS analysis and 
evaluate their in vitro free radical scavenging capacity.  
 
3)  Study pancreatic lipase mediated in vitro digestibility of diLaLA and 
trace free LA in plasma samples after oral administration of diLaLA to 
mice in a pilot study. 
 
4)  Evaluate the effects of diLaLA on body weight, food intake, and some 
clinical markers of lipid metabolism, in plasma and liver in diet 
induced obese (DIO) mice fed a high fat diet (HFD).  
 
5)  Investigate the effects of diLaLA on estimated stearoyl-CoA (SCD)-1 
activity in plasma, liver, and white adipose tissues and targeted genes 
LQYROYHGLQȕ-oxidation of fatty acids in the liver. 
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4  Materials and Methods  
This section briefly describes the materials and methods used in this thesis. The 
basic outline of the whole study and major analytical steps involved, are shown 
in Figure 9. In the first half of the study, two series of novel derivatives of LA 
with PS and 1,3-DAG were synthesized in our laboratory. In the second half of 
the study, similarly synthesized LA derivative with 1,3-dilaurin (1,3-dilauroyl-
2-lipoyl-sn-glycerol; diLaLA) was used for in vitro hydrolysis test (Paper III) 
and to evaluate anti-obesity effects by in vivo study (Papers IV-V). Since the in 
vivo study required pure novel derivative (diLaLA) in relatively large amount, 
diLaLA was obtained from a contract supplier, Onco Targeting AB (Uppsala, 
Sweden). Derivatives of LA with PS synthesized for their potential cholesterol 
reducing effects (Paper I), were not further studied for in vivo effects. Details of 
all the methods can be found in Papers I-V. 
4.1  Synthesis of novel derivatives (Papers I-II) 
Synthesis of LA derivatives with PS (Paper I) 
 
Two series of novel LA derivatives with PS and 1,3-DAG were synthesized 
according to a modified method, described by Chiu et al. (1996) and Uyeda et 
al. (2005). First, LA derivatives were synthesized with PS (phytosterol lipoate; 
PSLA), and phytosterol dihydrolipoate (PSDHLA) was obtained by reducing 
PSLA (Paper I). The synthesis reaction of LA derivatives with PS is shown in 
Figure 10. 
A PL[WXUHRI36FRQWDLQLQJȕ-sito-, campe-, stigma- and brassica- sterol 
was used for the synthesis of PSLA (Paper I). In brief, 1g PS, dissolved in 9 
mL CH2Cl2, was mixed with 64 mg 4-dimethyl amino pyridine (DMAP), 580 
mg LA, and 468 mg 1-ethyl-3-(3-dimethylainopropyl)-carbodiimide  34
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Figure 10. Synthesis of phytosterol lipoate (PSLA) and phytosterol dihydrolipoate (PSDHLA), 
showing beta-sitosterol as the example yielding: 1) beta-sitosterol lipoate, and 2) beta-sitosterol 
diyhydrolipoate. 
hydrochloride (EDCI) under N2 at 0 °C. After an overnight stirring at room 
temperature, the mixture was acidified with 1 M HCL and washed with 
aqueous saturated NaCl. The product was extracted twice with CH2Cl2, 
collected through dry Na2SO4. The synthesis reaction and purity of the product 
was primarily controlled by thin layer chromatography (TLC; Si gel 60, 10x20 
cm, 0.25 mm thickness), developed in hexane:diethyl ether:acetic acid 
(75:25:0.85, v/v/v). Compounds were visualized by spraying 10% 
phosphomolybdic acid solution in ethanol and dried at 120 °C for 15 min. 
Crude extract from synthesis was purified by solid phase extraction (SPE; 1 g 
silica) using hexane.  
The reducing reaction to obtain PSDHLA was performed according to 
Chittiboyina et al. (2006) with some modifications (Figure 10). Purified PSLA 
dissolved in CH2Cl2: EtOH (1:5, v/v) was mixed with NaBH4 in portions while 
LA Beta-sitosterol
Beta-sitosterol lipoate
Beta-sitosterol dihydrolipoate
2
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NaBH4
H H
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O H
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+36 
stirring under N2 at room temperature. After 2 h, the mixture was acidified with 
1 M HCl, washed with aqueous NaCl and extracted twice with CH2Cl2 passed 
through dry Na2SO4. After evaporating solvent, purification was performed by 
preparative TLC (Si gel 60, 10x20 cm, 0.50 mm thickness plates) using the 
solvent system mentioned above for PSLA. 
Synthesis of LA derivatives with 1,3-DAG (Paper II) 
 
In the second study, LA was esterified with 1,3-diolein (DO) to synthesize 
1,3-dioleoyl-2-lipoyl-sn-glycerol (DOLA), and 1,3-dioleoyl-2-dihydrolipoyl-
sn-glycerol (DODHLA) was obtained by chemical reduction (Figure 11). The 
esterification procedure was similar to the synthesis of PSLA as described 
above, except that the preliminary TLC control was performed using 
hexane:diethyl ether:ethyl acetate:acetic acid (75:20:5:1, v/v/v/v) solvent 
system. Purification of DOLA was performed by column chromatography (Si 
gel 60 Å, 200-400 mesh) and fractions were collected with hexane:diethyl 
ether:acetic acid (100:4:1, v/v/v).  
 
 
 
Figure 11. Synthesis of 1) 1,3-dioleoyl-2-lipoyl-sn-glycerol (DOLA), and 2) 1,3-dioleoyl-2-
dihydrolipoyl-sn-glycerol (DODHLA). 
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Purified DOLA dissolved in CH2Cl2:MeOH (1:5, v/v) was reduced to 
obtain DODHLA as mentioned above for PSDHLA. Purification of DODHLA 
was performed by column chromatography (Si gel 60 Å, 200-400 mesh) and 
fractions were collected with hexane:diethyl ether:acetic acid (100:1:0.1, 
v/v/v). More details of the methods can be found in Paper II.   
NMR analysis 
 
All novel conjugates synthesized above were confirmed by 
1H-, 
13C-NMR and 
2-D experiments (COSY, TOCSY and HSQC-dept), as explained in Paper I 
and II.  
4.2  RP-HPLC-MS analysis (Papers I-II) 
Novel LA and DHLA derivatives and initial compounds used in synthesis (PS, 
1,3-DO, LA and DHLA) were analyzed by RP-HPLC-MS using atmospheric 
pressure chemical ionization (APCI). The chromatographic and MS conditions 
are summarized in Table 4. LA, DHLA, PSLA and PSDHLA were analysed in 
negative mode, whereas PS, PSLA, 1,3-DO, DOLA and DODHLA were 
analyzed in positive ion mode. The compounds were identified by their 
respective mass spectra. The fragmentation pattern of the novel derivatives was 
studied and fragment ions were identified with reference to the ions observed 
in the initial compounds of each derivative. 
4.3  DPPH assay (Papers I-II) 
Free radical scavenging capacity of the novel derivatives was assessed using 
2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical according to Brand-
Williams et al. (1995). First 0.06 mmol/L DPPH in toluene was prepared. A 
series of concentrations for each test compound was prepared separately, using 
toluene as the solvent (Wettasinghe & Shahidi, 2000). Concentrations of LA 
and derivatives of LA were prepared to obtain final molar ratio (MR) of 1-8 or 
1-12 between test compound and DPPH in the final mixture. Concentrations of 
DHLA and DHLA derivatives were prepared between 0.025-1.0 MR. Each 
concentration of all compounds was analyzed in triplicates using 0.1 mL test 
compound mixed with 3.9 mL DPPH in toluene. Absorbance was measured at 
515 nm, using toluene as the blank sample, every 15 min until steady state. The 
PHDQRIUHPDLQLQJ'33+IUHHUDGLFDO'33+Úat steady state was plotted to 
study the reaction kinetics of novel derivatives. Free radical scavenging 39 
capacity defined as efficient concentration (EC50) for DHLA and DHLA 
derivatives was calculated using the respective kinetic curves. 
4.4  In vitro hydrolysis of novel derivative - diLaLA (Paper III) 
As mentioned earlier, pure R-(+)-LA conjugated with 1,3-dilaurin (1,3-
dilauroyl-2-lipoyl-sn-glycerol; diLaLA) was studied for in vitro hydrolysis, in 
a pilot study prior to an in vivo study. The in vitro hydrolysis was performed 
using porcine pancreatic lipase (type II), according to a combined method 
described previously (Narayan et al., 1993; Sahin et al., 2005). In brief, 
porcine lipase (0.3% of reaction medium; wt./wt.) dissolved in 7 mL Tris 
buffer at pH 8 was mixed with 25 mg diLaLA dissolved in 100 L hexane. 
Then 0.25 mL 0.05% bile salt and 2.2% calcium chloride per mL buffer were 
added and incubated at 38±2 ÛC with continuous agitation. In vitro hydrolysis 
was tested in triplicate at 5, 15, 30, 60 and 120 min incubation periods to 
monitor the formation of products by hydrolysis. The hydrolysis pattern was 
primarily monitored by analytical TLC developed in hexane:diethyl 
ether:acetic acid (50:50:1, v/v/v), and visualized by exposing the plate to iodine 
vapor for 10 min. At the end of the incubation time, the mixture was acidified 
to pH 2, after the TLC control. The digestion products were extracted with 
diethyl ether and analyzed by RP-HPLC-MS. Chromatographic and MS 
conditions used, are summarized in Table 4.  
In addition, a preliminary test was performed to trace free LA in blood 
samples after a single oral treatment of 250 mg diLaLA/kg body wt. in lean 
C57/BL6J mice (details of the animals and sample collection is given under in 
vivo test below & Table 5). Blood samples collected after 2 h and 18 h, pooled 
separately, lipids were extracted (Folch method, 1957) and analyzed for free 
LA and C12:0 using RP-HPLC-MS-ESI (Table 4). 
4.5 Study  design:  In vivo trial (Papers IV-V) 
Novel molecule diLaLA was evaluated for potential biological effects against 
HFD induced obesity using obese C57BL/6J male mice (Taconic, USA), orally 
treated with diLaLA dissolved in rapeseed oil (used as vehicle). The study was 
approved by the animal experimental ethical committee (Dnr: C189/11) and 
conducted at Contract In Vivo Design (Uppsala, Sweden). In addition to DIO 
mice, an extra group of age matched lean male mice (Lean) was included as a 
parallel study and their blood samples were used in Paper III. Details of 
treatment groups, research diets and dose levels of the test compound are given 40 
in Table 5 and Papers IV-V. The mice were around 16 weeks old and grouped 
based on their initial body weight.  
Mice were housed as 2-3 mice/cage and had free access to food and water. 
During a 10 day acclimatization period, DIO mice were fed a HFD (product 
no. D 12451; 45% of total calories from fat; 4.73 kcal/g) purchased from 
Research Diet Inc. (New Brunswick, NJ, USA) and lean group was fed an 
ordinary rodent chow diet (3 kcal/g) obtained from Lantmännen (Kimstad, 
Sweden). The treatment was conducted for 6 weeks, and DIO mice were fed 
the same HFD, throughout the treatment period. The lean group was introduced 
to above mentioned HFD, at the start of the experiment. Body weight and 
cumulative food intake (CFI) were recorded 2-3 times/week, during the 
treatment period.  
Animals were observed for general behavior, clinical signs of toxicity, 
motor activity and fur quality. On the last day of the treatment, lean mice were 
treated with 250 mg/diLaLA/kg body wt. and blood samples were collected at 
regular intervals during 0.5-18 h after administration. These plasma samples 
were used in Paper III. At sacrifice macroscopy was performed, the liver was 
inspected for steatosis and liver weight was recorded. Plasma, liver and white 
adipose tissue (AT) samples were frozen immediately and stored at -80 Û&XQWLO
further analysis. Further details of clinical observations, termination of the 
experiment and sample collection are given in Papers IV-V. A deviation report 
on mice excluded from the study is attached as a supplement report in the 
appendix to Paper IV.  
Table 5. Allocation of test animals, diets and dose levels among different treatment groups of 
BL57/6J male mice (Papers III-V) 
Parameter  Diet induced obese (DIO)  
(Papers IV-V) 
Lean 
(Paper III)  
Treatment group  DIO-V  DIO-10  DIO-50  DIO-250  Lean 
Type of diet  HFD HFD HFD HFD HFD 
No. of animals/group (n)  7 7 7 7 7 
Initial  body  wt.  (g)  36.7±2.2 35.8±2.9 36.3±1.8 35.9±3.7 26.1±1.9 
Dose of diLaLA (mg/kg 
body wt./d) dissolved in 
vehicle (V) 
0+V  10+V  50+V 250+V 50+V 
Abbreviations: HFD, high fat diet containing 45% of total calories from fat; n, number of male mice allocated 
per each treatment group at the beginning of the study; diLaLA, test compound 1,3-dilauroyl-2-lipoyl-sn-
glycerol; V, vehicle (rapeseed oil) used to dissolve diLaLA. The test compound and/V was orally administered 
by gavage, daily for 6 weeks. 41 
4.5.1 Biochemical  analysis 
DIO mice fed with HFD, were used to evaluate effects on obesity in this thesis. 
Blood samples from non-fasting animals were analyzed for glucose levels 
using Accu-Chek® Aviva from Roche (Mannheim, Germany) according to the 
manufacturer’s instructions. After studying body weight, CFI and blood 
glucose concentration data, it was decided to analyze lipids in plasma, liver and 
AT samples only from DIO-V and DIO-250 groups, for practical reasons. 
Detailed methods of all biochemical analysis are given in Papers IV-V. 
Concentrations of TAG and FFA were quantified using heptadecanoic acid 
(C17:0) and triheptadecanoin as internal standards (IS), added to plasma. 
Lipids were extracted using a slightly modified version of the method by Folch 
et al. (1957), and FFA and TAG fractions were separated by preparative TLC 
using hexane:diethyl ether:acetic acid, (85:15:1, v/v/v) solvent system. Fatty 
acid methyl esters (FAME) of FFA and TAG were prepared by in-situ 
methylation and analyzed by GC (Glaser et al., 2010). A recovery test was 
performed similarly, using standard oleic acid and triolein spiked in pooled 
plasma samples (n = 3), and recovery % was calculated based on non-spiked 
controls (n = 3).  
Total cholesterol (T-Ch) and total fatty acid composition (TFA) in plasma 
and liver samples were TXDQWLILHGXVLQJĮ-cholestane and C17:0, respectively, 
as IS. Samples were saponified directly according to a combined method (Rule 
et al., 2002; Ubhayasekera et al., 2010). The non-saponifiable fraction was 
extracted, silylated and analyzed for T-Ch by GC. Remaining saponifiable 
fraction with IS C17:0 was extracted and methylated to analyze TFA. 
Similarly, white AT samples were directly saponified and analyzed for TFA 
(Lepage & Roy, 1984). Stearoyl-CoA desaturase (SCD)-1 activity was 
estimated by SCD16 index (palmitoleic acid, C16:1n-7/palmitic acid, C16:0) 
and SCD18 index (oleic acid, C18:1n-9/stearic acid, C18:0) using TFA data 
from plasma, liver and white AT samples (Warensjö et al., 2009). Vitamin E 
Į-tocopherol) content in plasma and liver samples was quantified by HPLC 
using an external standard method (Azardmard-Damirichi & Dutta, 2008) after 
extracting lipids, according to the method of Hara & Radin (1978).  
4.5.2  Gene expression analysis  
 
Liver samples from the DIO-250 (n  = 3) and DIO-V (n  = 2) groups were 
analysHGIRUWDUJHWJHQHVLQYROYHGLQȕ-oxidation and energy metabolism using 
RT-qPCR (Qiagen Gmbh, Hilden, Germany). Each sample was analysed in 
duplicate and average expression level was calculated separately for all the 
genes analysed. Relative expression levels for each gene in liver samples of 42 
DIO-250 were expressed as fold change, compared with DIO-V. All data were 
calculated using on line RT
2 Profiler
TM PCR Array Data Analysis version 3.5 
Qiagen (Qiagen Gmbh, Hilden, Germany) and statistical comparison between 
two treatment groups was not performed due to limited number of replicates in 
DIO-V. Details of the method are found in paper V. 
4.5.3 Statistical  analysis   
 
Results from in vitro tests are expressed as mean±standard deviation (SD), 
(Papers I-II) and results from animal experiment and biochemical analysis as 
mean±standard error of mean (SEM). Data on body weight, CFI, blood glucose 
and liver weight in DIO groups were analyzed using one way analysis of 
variance (ANOVA) and treatment groups were compared using Bonferroni´s or 
Dunnet´s multiple comparision test. Results from biochemical analysis of 
plasma, liver and white AT samples of the DIO-250 and control groups were 
compared using a two sample t-test assuming equal variance. Differences were 
considered significant at p<0.05. All statistical analysis were performed using 
the software, GraphPad Prism (GraphPad Software Inc., California, USA) and 
Minitab version 16.0 (Minitab Inc., State College, PA, USA). 
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5  Results and Discussion  
5.1  Synthesis of novel derivatives  
Two series of LA and DHLA derivatives with PS and 1,3-DAG were prepared 
by a simple two step procedure (Figure 10 & 11), performed under mild 
conditions. In the first step, LA with PS or 1,3-DAG was esterified, in the 
presence of DMAP and EDCl. In the second step, the disulfide bond was 
reduced using NaBH4 to obtain DHLA derivatives of either PS or 1,3-DO. 
Among different solvent systems tested for TLC control, hexane:diethyl 
ether:acetic acid (75:25:0.85, v/v/v) showed satisfactory separation of the non-
polar derivatives PSLA and PSDHLA, as well as the initial polar compounds 
PS and LA (results are not shown).  
Synthesis of DOLA and DODHLA was performed similarly, except that 
TLC control (Figure 12) was performed using the solvent system 
hexane:diethyl ether:ethyl acetate:acetic acid (75:20:5:1, v/v/v/v). Purified 
novel derivatives PSLA, PSDHLA, DOLA and DODHLA were characterized 
by NMR analysis (Papers I & II). Novel derivatives PSLA and DOLA showed 
yield of approx. 60% and 80%, respectively, after purification by 
chromatographic methods. Both of the products remained as light yellow 
colored oils, in the room temperature in contrast to LA and PS which occur as 
powder and are poorly soluble in oil or water.  
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Figure 12. Thin layer chromatogram (TLC) showing the separation of initial compounds and 
novel derivatives (Paper II). TLC was developed in hexane:diethyl ether:ethyl acetate:acetic acid 
(75:20:5:1, v/v/v/v) and compounds were visualized by spraying phosphomolybdic acid to 
GHYHORSFRORUDWÛ&IRUPLQ. $EEUHYLDWLRQV/$Į-lipoic acid; DHLA, dihydrolipoic acid; 
1,3-DO, 1,3-dioleoyl-sn-glycerol; DOLA, 1,3-dioleoyl-2-lipoyl-sn-glycerol, and DODHLA, 1,3-
dioleoyl-2-dihydrolipoyl-sn-glycerol. 
5.2 RP-HPLC-MS-APCI  analysis 
Derivatives of LA with phytosterols (Paper I) 
 
As expected, the polar initial compounds LA and DHLA showed relatively 
higher signal in ESI mode, whereas 1,3-DO, PS and non-polar conjugates after 
esterification showed higher signal in APCI mode. LA and DHLA were 
analyzed in negative ion mode, due to their acidic properties. However, they 
were co-eluted due to the high proportion of organic solvent used in the mobile 
phase. Since our main focus was to study the novel derivatives, high organic 
proportion in the mobile phase and APCI mode were selected for further 
analysis.  
In the case of PS derivativHVDVDWLVIDFWRU\VHSDUDWLRQRIGLIIHUHQW36ȕ-
sito-, campe-, stigma- and brassica- sterols) and their LA derivatives could be 
achieved with C8 column DWÛ&FROXPQWHPSHUDWXUH(Figure 13) compared 
with the C18 columns tested (details in Paper I). Among the PS, brassicasterol 
was eluted first, followed by campesterol and stigmasterol whereas sitosterol 
was eluted last. However, a baseline separation between campesterol and 
stigmasterol could not be achieved even with C8 column and the method may 45 
need further optimization. Corresponding LA and DHLA derivatives of PS 
eluted later, but followed the same order. A mixture of PS was used in the 
synthesis of PSLA, since this was commercially more feasible compared to 
expensive pure PS. The composition of this initial PS mixture was pre-
analyzed by GC in our laboratory and found to contain 53, 29, 15 and 1% RIȕ-
sito-, campe-, stigma- and brassica- sterol, respectively. Similar proportions of 
corresponding PSLA derivatives were observed after the esterification reaction 
when analyzed by RP-HPLC-MS.  
 
Figure 13. Total ion chromatogram recorded in positive ion mode in RP-HPLC-MS-APCI, 
showLQJVHSDUDWLRQRIȕ-sito-, stigma-, and campe- sterols in the initial PS mixture, and their 
derivatives with LA.  
Different PS and their PSLA derivatives provided relatively higher signal in 
positive mode, whereas PSDHLA showed higher signal in the negative mode. 
The dominant and characteristic ions observed for the novel derivatives 
demonstrated their fragmentation pattern (Paper I). PS showed typical 
dehydrated ion, [M-H2O+H]
+, along with [M-2H+H]
+ and [M-4H+H]
+ ions, as 
described previously (Rozenberg et al., 2003; Bedner et al., 2004). In positive 
mode, the protonated molecular ion [M+H]
+ was characteristic in all PSLA 
molecules showing ions at m/z 603, 601, 589 and 587 IRUȕ-sito-, stigma-, 
campe-, and brassica- sterol lipoate, respectively. At the same time, fragment 
ions at m/z 397-, 395-, 383-, and 381- confirmed their corresponding 
characteristic PS moiety from ȕ-sito-, stigma-, campe-, and brassica- sterol, 
respectively. The fragmentation at the esterified position was further illustrated 
by the dominant fragment ion at m/z 205 from LA moiety observed in the 46 
negative ion mode analysis of PSLA. Dominant [M-H]
- was observed for 
PSDHLA in the negative mode.  
Derivatives of LA with 1,3-DAG (Paper II) 
 
Among different columns tested, C18 column was proved suitable for 
separation of LA, DO, DOLA and DODHLA (Figure 14). When retention 
times of LA derivatives were compared with their corresponding DHLA 
derivatives, DHLA derivatives eluted before their corresponding LA 
derivatives. LA derivatives with the closed dithiolane ring showed a more 
hydrophobic nature compared to their reduced counterparts which possess an 
open ring with two thiol groups.  
 
Figure 14. Total ion chromatogram recorded in RP-HPLC-MS-APCI showing retention times of 
the initial compounds and their derivatives $EEUHYLDWLRQV  /$ Į-lipoic acid; 2) DHLA, 
dihydrolipoic acid; 3) 1,3-DO, 1,3-dioleoyl-sn-glycerol; 4) DOLA, 1,3-dioleoyl-2-lipoyl-sn-
glycerol, and 5) DODHLA, 1,3-dioleoyl-2-dihydrolipoyl-sn-glycerol.  
In the case of DO, DOLA and DODHLA, relatively higher signal was 
observed in positive ion mode. Due to its hydroxyl group at the –sn2 position, 
DO produced the dominant [M-H2O+H]+ ion at m/z 603. In addition, ion at m/z 
339 showed dissociation of one FA from DO, resulting in a protonated MAG 
[M-RCOOH+H]
+ while molecular ion at m/z 621 was less abundant. In 47 
contrast, DOLA was relatively more stable and showed the dominant 
molecular ion at m/z 809 and fewer fragment ions. However, fragment ions at 
m/z 527 and 339 reflected some formation of [M-R1COOH+H]
+ and [M-
R1COOH-R2COOH+H2O+H]
+ ions, respectively. DODHLA showed a similar 
fragmentation pattern, but the dominant ion was m/z 529 fragment ion [M-
R1COOH+H]
+ with less abundant molecular ion [M+H]
+.  
5.3  Free radical scavenging capacity 
The results from the DPPH assay showed that the in vitro free radical 
scavenging capacity of PSLA and DOLA was very low and comparable to the 
free radical scavenging capacity and kinetics observed for LA.  In contrast, 
PSDHLA and DODHLA showed high interaction with DPPH free radical and 
were comparable with DHLA (Figure15). Reaction kinetics was plotted using a 
series of concentrations for each test compound, as described by Brand-
Williams et al. (1995). At MR = 1, the remaining DPPH% was only 18% in 
PSDHLA, whereas it was 99% in PSLA. Similarly, DOLA and LA also 
showed more than  UHPDLQLQJ '33+Ú, whereas DHLA and DODHLA 
VKRZHG  DQG  UHPDLQLQJ '33+Ú, respectively, when MR = 1. The 
relatively longer time taken to achieve steady state in DHLA, PSDHLA and 
DODHLA compared to LA and LA derivatives suggests continuous interaction 
of novel derivatives ZLWK'33+Ú. 
The antioxidant properties of LA is believed to be due to the intra-
molecular disulphide bond in the dithiolane ring of LA, which possesses high 
electron density due to its special position of the two sulfur atoms (Packer et 
al., 1995; Biewenga et al., 1997). In biological systems LA is enzymatically 
reduced to DHLA, which is considered more potent antioxidant due to its two 
thiol groups (Teichert & Preiss, 2008). High antioxidant capacity of DHLA 
compared with LA is well documented (Packer et al., 1995; Biewenga et al., 
1997; Shay et al., 2009). However, LA did not show sufficient interaction with 
'33+Ú IUHH UDGLFDl in present study. In this thesis, in vitro free radical 
scavenging capacity of novel LA and DHLA derivatives was analyzed and 
compared with that of pure LA and DHLA to determine, whether conjugation 
has any effect on the potential antioxidant properties. The results observed 
showed that conjugation did not affect the free radical scavenging capacity of 
novel derivatives.  
6WDEOH'33+ÚIUHHUDGLFDOLVFRQVLGHUHGVXLWDEOHIRUDQDO\VLVZLWKOLSRSKLOLF
compounds, performed at micro-molar levels (Brand-Williams et al., 1995). 
Due to their nonpolar nature, PSLA and DOLA are not completely soluble in 
methanol or ethanol, which are considered typical solvents for the DPPH test. 48 
Therefore toluene was used as the solvent in DPPH assay, according to 
Wettasinghe & Shahidi (2000). Since, there were no previously published data 
on the in vitro free radical scavenging capacity of LA and DHLA using toluene 
as solvent, they were also evaluated under similar conditions, in order to 
compare with novel conjugates. The effective concentration EC50 is known as a 
comparative measurement of antioxidant capacity between different 
antioxidant compounds (Brand-Williams et al., 1995). The EC50  values 
obtained from the kinetic curves for DHLA, PSDHLA and DODHLA were 
0.39±0.04, 0.43±0.05 and 0.22±0.03, respectively. The variation between 
different compounds can be due to the molecular structure and differences in 
the solubility of test compounds. In addition to the reducing capacity of the test 
FRPSRXQGWKHLQWHUDFWLRQEHWZHHQ'33+ÚPD\also vary between different 
compounds due to steric hindrance depending on molecular structure and 
differences in solubility (Brand-Williams et al., 1995).  
 
Figure 15. Free radical scavenging capacity of novel derivatives measured by DPPH assay. 
Results are expressed as remaining DPPH free radical (%) as a function of molar ratio between 
testing compound and DPPH free radical. $EEUHYLDWLRQV/$Į-lipoic acid; DHLA, dihydrolipoic 
acid; DOLA, 1,3-dioleoyl-2-lipoyl-sn-glycerol, DODHLA, 1,3-dioleoyl-2-dihydrolipoyl-sn-
glycerol; PSLA, phytosterol lipoate; PSDHLA, phytosterol dihydrolipoate.  
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5.4  In vitro digestion of diLaLA  
In vitro hydrolysis of diLaLA was performed by simulating conditions similar 
to the small intestine, but with excess pancreatic lipase to ensure that the 
reaction was not substrate-limited. Intermediate product 1(3)-lauryl-2-lipoyl-
sn-glycerol was observed in incompletely hydrolyzed mixtures, during 
optimization of the reaction and when diLaLA was not initially dissolved in 
100  L hexane as described by Narayan et al. (1993). After optimization, 
major products from the hydrolysis at the initial stage were lauric acid (C12:0) 
and MAG (Figure 16). The amount of free LA increased gradually from 
approx. 3% at 5 min up to 20% by 60 min of the incubation time (Figure 17). 
The concentration of free LA increased until 60 min while the MAG 
concentration decreased, showing further hydrolysis of monolipoate. Under the 
test conditions, pancreatic lipase showed hydrolysis of LA, esterified at the sn-
2 position in the diLaLA molecule, in addition to its well documented 
hydrolysis at the –sn1 and the –sn3 positions. It has been found that pancreatic 
lipase can hydrolyze FA at the –sn2 position in TAG depending on the 
incubation time, enzyme concentration, temperature and type of lipase enzyme 
(Jennings & Koh, 1999).  
 
Figure 16. Chemical structure of the products formed in in vitro hydrolysis of novel derivative 
1,3-dilauroyl-2-lipoyl-sn-glycerol (diLaLA), mediated by porcine pancreatic lipase (Type II). 
Products identified using RP-HPLC-MS-ESI: 1) 1(3)-lauroyl-2-lipoyl-sn-glycerol; 2) 2-lipoyl-sn-
glycerol (monolipoate); 3Į-lipoic acid (LA); 4) 1(3)-lauroyl-sn-glycerol (monolaurate), and 5) 
lauric acid (C12:0). 
The concentration of C12:0 was slightly reduced until 60 min, probably due 
to acyl migration, that might have occured between partial glycerides during 
pancreatic hydrolysis (Jennings & Koh, 1999; Christophe, 2008). The MAG 
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fraction observed at 15 min was isolated by preparatory TLC and analyzed by 
RP-HPLC-MS showed that 78% of it comprised monolipoate, whereas 14% 
was monolaurate. Since pure standard was not available, formation of 
monolipoate during incubation was followed by monitoring the area recorded 
by SIM chromatogram for selected characteristic ions at m/z 263 and m/z 298. 
The TLC control and RP-HPLC-MS analysis showed that in vitro hydrolysis of 
diLaLA was completed within 15 min, releasing monolipoate, monolaurate, 
free C12:0 and LA under the test conditions. 
 
 
Figure 17. Formation of digestion products during in vitro hydrolysis of novel TAG molecule 
(diLaLA) using porcine pancreatic lipase (Type II) at 8 pH and 38±2 °C. Each point is 
mean±SEM of triplicates analyzed by RP-HPLC-MS-ESI. 
Identification of free LA and C12:0 in mice plasma (Paper III) 
 
For the first time, free LA and C12:0 were observed in the lipid extract of a 
pooled plasma sample collected after 2 h oral administration of 250 mg 
diLaLA/kg body wt. in lean mice (Figure18). The peaks were identified by 
comparing them with the respective mass spectra and retention times of 
standard LA and C12:0 (Paper III). Despite co-eluting unknown compounds, 
negative deprotonated ion [M-H]
- at m/z 205 and characteristic fragment ion 
[M-H2S-H]
- at m/z 171 provided enough evidence to identify free LA in plasma 
sample as observed in previous studies Papers I-II, and previous literature 
(Montero et al., 2012). Neither LA nor C12:0 was observed in plasma samples 
collected 18 h after oral administration of diLaLA. According to the literature, 
orally ingested pure LA is absorbed directly, metabolized rapidly and excreted 
via urine (Schupke et al., 2001; Teichert & Preiss, 2008). 
 
0
100
200
300
400
500
600
700
800
0 2 04 06 08 0 1 0 0 1 2 0 1 4 0
F
r
e
e
 
a
c
i
d
 
(
ђ
g
/
m
g
 
1
,
3
-
d
i
L
a
L
A
)
Incubation time (min)
ɲ-LA
C12:0
0
10
20
30
40
50
60
0 2 04 06 08 0 1 0 0 1 2 0 1 4 0
2
-
l
i
p
o
y
l
-
s
n
-
g
l
y
c
e
r
o
l
 
(
A
.
U
.
x
1
0
0
0
)
Incubation time (min.)
SIM-2(298 m/z)
SIM-3 (263 m/z)51 
 
Figure 18. Free Į-lipoic acid (LA) and lauric acid (C12:0) detected in lipids, extracted from a 
pooled plasma sample 2 h after oral treatment with 250 mg diLaLA/kg body wt. in lean mice. 
Lipid extract was analyzed using RP-HPLC-MS-ESI in negative ion mode. Abbreviations: a) 
TIC, total ion chromatogram of plasma lipid extract; b) SIM at m/z 205, selective ion monitoring 
chromatogram at m/z 205 for LA, and c) SIM at m/z 199,  selective ion monitoring chromatogram 
at m/z 199 for C12:0. 
5.5  Anti-obesity effects of diLaLA 
Clinical observations(Papers IV-V) 
 
During the study, three mice in the DIO-10 group were excluded, one mouse 
due to failure in oral gavage and two due to physical injuries that affected food 
intake (FI) and weight gain. During clinical observations, no signs of 
substance-related toxicity, was observed. Furthermore, there were no toxic- or 
pathological- symptoms in relation to administration of vehicle or test 
compound. At sacrifice, steatosis was observed in one animal from each group. 
Weight of the liver among different groups did not show any significant 
difference (Table 6). The C57BL/6J mice model is widely considered a reliable 
and robust experimental model to evaluate the effect of novel therapeutic 
interventions related to diet induced obesity (Winzel & Ahrén, 2004). 
 52 
5.5.1  Effects on body weight and food intake 
 
The body weight of all DIO mice on HFD was increased in all treatment 
groups during the 6 week treatment period, except in DIO-250 group (Figure 
19) which showed significant difference (p<0.05) compared with the control 
group treated vehicle alone (DIO-V) or the low dose (DIO-10 and DIO-50) 
groups. At the end of the 6 weeks treatment, only the high dose group, DIO-
250 showed a significant effect on body weight change demonstrating a loss in 
body weight compared with other groups (p<0.05) who clearly gained weight 
over time (Figure 20).  
 
Figure 19. Changing pattern of the body wt. in different treatment groups of diet induced obese 
(DIO) male mice fed a high fat diet (HFD) during 6 weeks treatment with 1,3-dilauroyl-2-lipoyl-
sn-glycerol (diLaLA). Mice in treatment groups DIO-V, DIO-10, DIO-50 and DIO-250 were 
orally treated with diLaLA, dissolved in vehicle (rapeseed oil) at dose levels 0, 10, 50 and 250 
mg/kg body wt., respectively. 
 
Figure 20. Body weight change observed in different treatment groups at the end of 6 weeks 
treatment with diLaLA. Abbreviations and dose levels as described in Figure 19. 
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Doses at 10 or 50 mg/kg body wt. showed non-significant changes in body 
weight gain at the end, compared with the control suggesting that tested low 
oral doses of diLaLA were not sufficient to deliver any weight reduction. Thus 
oral administration of diLaLA at 250 mg/kg body wt. daily, for 6 weeks was 
effective in reversing HFD induced body weight gain in DIO mice, compared 
with the control. 
A dip in body weight gain observed during the second week of the 
treatment, was not related to diLaLA since it was also observed in the control 
group. This could be due to some physical strain caused by gavage feeding. 
The animals were housed in groups of two or three per cage, for practical 
reasons and cumulative food intake (CFI) was calculated for each group based 
on the FI data on cage basis. A marginally lower CFI was observed in all 
diLaLA treated mice compared with the control, indicating some reduction in 
CFI, but there were no significant difference between treatment groups (Table 
6).  
Since this was the first study on the novel derivative diLaLA, there were no 
previously published data on weight-reducing effects to compare the results. 
Previously published data on oral supplementation with pure LA have shown a 
significant reduction in body weight in rodents (Kim et al., 2004; Cremer et al., 
2006; Park et al., 2008; Prieto-Hontoria et al., 2009; Wang et al., 2010). 
However, a concomitant reduction in FI in the rodents tested,  were observed in 
all those studies except that by Ide et al. (2013), who did not observe any 
significant reduction in FI, similar to present data. Therefore the results 
support, the idea that there is another mechanism underlying the body weight-
reducing effect mediated by diLaLA. Wang et al. (2010) found that the 
respiratory quotient (volume CO2/volume O2) in LA treated C57BL/6J mice 
was higher than that in the control, suggesting higher energy expenditure 
induced by LA. Moreover, dietary supplementation of LA (0.5% wt./wt.) in 
rats was reported to up regulate expression of uncoupling protein (UCP)1 in 
brown AT. UCP1 is located in the inner mitochondrial membrane and dissipate 
proton electrochemical energy as heat, regulating energy expenditure in 
rodents (Kim et al., 2004).  
The weight-reducing effect mediated by consumption of 1,3-DAG replacing 
TAG in the diet, was also explained by enhanced energy expenditure through 
FA oxidation and thermogenesis, in rodents as well as humans (Maki et al., 
2002; Murase et al., 2002; Rudowska et al., 2005; Hibi et al., 2008). In 
addition, DVHURWRQLQPHGLDWHGLQFUHDVHLQȕ-oxidation of FA has also been 
suggested for 1,3-DAG induced weight reduction (Yanai et al., 2010).  54 
Table 6. Effect of orally administered 1,3-dilauroyl-2lipoyl-sn-glycerol (diLaLA) in DIO mice on 
high fat diet at the end of the 6 weeks treatment period (Paper IV) 
Parameter DIO-V  DIO-10  DIO-50  DIO-250 
CFI  (kcal/kg  body  wt.)  1618±90 1515±82 1429±38 1493±42 
Liver  weight  (g)  1.4±0.1 1.3±0.1 1.4±0.1 1.3±0.1 
Blood glucose con.  (mmol/L)  9.6±0.5  9.8±0.9  9.8±0.2  8.6±0.4 
TAG con. in plasma (mg/dL)  45.7±7.2  NA  NA  59.7±3.6 
TAG con. in liver (mg/g)  62.0±13.2  NA  NA  51.3±12.3 
Vitamin E con. in plasma (g/dL) NA  NA  343.9±62.4  438.1±51.7 
Vitamin E con. in liver (g/g) 47.1±7.6  NA  NA  48.1±7.5 
Abbreviations: CFI, cumulative food intake; TAG, triacylglycerol; DIO, diet induced obese mice; V, control 
treated only with vehicle; -10, -50, -250, treated with diLaLA at -10, -20 and -250 mg doses/kg body wt. daily 
for 6 weeks, respectively; con., concentration in samples from non-fasting animals; NA, not analyzed. All 
values are mean±standard error of mean, no. of animals (n)/group  = 7, except for DIO-10 where n = 4. 
Effects on blood glucose concentration 
 
The blood glucose concentration in DIO-250 was the lowest among all groups, 
while that in DIO-V, DIO-10 and DIO-50 was rather uniform (Table 6). 
Although difference between the DIO-250 and the DIO-V was not significant, 
this might indicate a trend for reducing glucose concentration. This was 
probably due to improved insulin sensitivity. According to previous literature 
dietary supplementation of LA increase glucose uptake and insulin sensitivity 
in rodents as well as humans (Kim et al., 2004; Shay et al., 2009; Wang et al., 
2010; Packer & Cadenas, 2011). This is further supported by significantly low 
FFA concentration observed in DIO-250 mice compared with the control, 
which will be discussed later in this thesis. 
5.5.2  Effects on lipids in plasma and liver 
Effects on total cholesterol concentration 
 
The concentrations of T-Ch in both plasma and liver samples from DIO-250 
mice were relatively low compared with the control DIO-V, although 
significant differences were not observed (Figure 21). Supplementation of pure 
LA was reported to reduce total cholesterol in serum and liver in rodents (Yang 
et al., 2008; Ide et al., 2013). A previous study with C57BL/6J mice 
supplemented with LA (0.1% wt./wt.) in HFD reported decrease in plasma T-
Ch and LDL-Ch, mediated by down regulation of genes involved in the 
cholesterol synthesis pathway (Yang et al., 2008). Moreover, there might be a 
parallel effect of body weight reduction, since plasma cholesterol shows a 55 
positive correlation with body weight (Poobalan et al., 2004; Miller et al., 
2011). 
 
Figure 21. Concentration of total cholesterol and free fatty acids in plasma and liver samples of 
diet induced obese (DIO) mice, after 6 weeks treatment with 1,3-dilauroyl-2-lipoyl-sn-glycerol 
(diLaLA). Abbreviations: DIO-250, DIO mice treated with diLaLA 250 mg/kg body wt. daily; 
DIO-V, control treated only with vehicle. Values are mean±standard error of mean (n = 7). 
Effects on TAG concentration 
 
The results from the recovery test showed 91±4% recovery for TAG analyzed, 
by preparative TLC method used in this thesis. The total plasma and hepatic 
TAG concentrations between DIO-250 and the control DIO-V did not differ 
significantly (Table 6), probably due to the high variation observed among 
animals and the small group size (n = 7). In contrast to other results observed 
in DIO-250 mice, plasma TAG concentration was higher compared with the 
control. This unexpected result was probably due to time of sampling in 
relation to food intake. The mice in the present study had free access to food 
and were non-fasting when sacrificed.  
On the other hand, total hepatic TAG concentration observed in DIO-250 
mice was 17% lower compared with the control and was in agreement with 
other results observed in the study. According to the literature, liver TAG 
generally reflects relatively long term effects compared with the plasma TAG 
and only 9-13% of dietary TAG are recycled through the liver daily (Lambert 
& Parks, 2012). The reduced TAG concentration observed in the liver of DIO-
250 mice is in agreement with previously published data in rats supplemented 
with LA (Park et al., 2008). The concentration of individual FA observed in 
TAG fraction was proportionately lower in DIO-250 mice, compared with the 
control (Figure 22). However, the relative % of individual FA remained rather 
uniform between DIO-250 and control. The concentrations were reduced in the 
major FA, C18:1(n-9), C16:0 and C18:2(n-6) which comprised approx. 38%, 
25% and 21% of the total amount, respectively. 
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Figure 22. Concentration of individual fatty acids in the triacylglycerol fraction in liver samples 
of diet induced obese (DIO) mice, after 6 weeks treatment with 1,3-dilauroyl-2-lipoyl-sn-glycerol 
(diLaLA). Abbreviations: DIO-250, DIO mice treated with diLaLA 250 mg/kg body wt. daily; 
DIO-V, control treated only with vehicle. Values are mean±standard error of mean (n = 7). 
Effects on FFA concentration 
 
Oral administration of diLaLA at 250 mg/kg body wt. resulted in significant 
decrease in total FFA concentration in both plasma (p<0.05) and liver (p<0.01) 
compared with the control group (Figure 21). In DIO-250 mice, plasma FFA 
concentration was reduced by 26%, while liver FFA concentration was reduced 
by 38%. The recovery test showed 99±23% recovery, for FFA analyzed by 
preparative TLC method used in this thesis. Among individual FFA observed, 
concentrations of C16:0, C16:1n-9, C16:1n-7, C18:1n-9, C18:2n-6, C20:4 and 
C22:6 were significantly lower (p<0.05) in plasma (results are not shown). In 
liver samples, all identified individual FFA, except C12:0, C14:0, C16:1n-9 
and C16:1n-7 were significantly lower (p<0.05) in DIO-250 mice, compared 
with the control (Figure 23). However, the relative % of individual plasma 
FFA between DIO-250 and the control remained constant. The major FFA in 
both plasma and liver were C16:0, C18:1(n-9) and C18:2(n-6). 
These findings are in agreement with previous studies on rats supplemented 
with LA in the diet (Kim et al., 2004; Park et al., 2008). Increased FFA 
concentration in plasma is commonly associated with obesity and has been 
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identified as an important factor behind insulin resistance (Boden, 2008; 
Cedernaes et al., 2013). Extra FFA provided by visceral AT to the liver, are re-
esterified to TAG, resulting in increased concentrations of VLDL which is 
believed to generate atherogenic LDL-Ch (Miller et al., 2011). Therefore the 
diLaLA-induced decrease, in plasma and liver FFA concentrations in diet 
induced obese mice in this thesis, highlights the potential positive health 
effects of this novel derivative against obesity associated risk factors.  
 
Figure 23. Concentration of individual fatty acids in the free fatty acid fraction in liver samples of 
diet induced obese (DIO) mice after 6 weeks treatment with 1,3-dilauroyl-2-lipoyl-sn-glycerol 
(diLaLA). Abbreviations: DIO-250, DIO mice treated with diLaLA 250 mg/kg body wt. daily; 
DIO-V, control treated only with vehicle. Values are mean±standard error of mean (n = 7). 
5.5.3  Effects on estimated SCD1 activity 
 
The results in this thesis show that estimated SCD16 index (16:1n-7/16:0) was 
significantly reduced (p<0.05) in white AT of DIO-250 mice compared with 
the control, while a similar trend was found in liver samples (Figure 24). 
However, no difference in SCD16 index was observed in plasma. This could 
be due to the relatively short duration of the experiment, because AT are 
known to reflect earlier changes in obesity compared with liver and plasma 
samples (Cedernaes et al., 2013). Lipogenic enzyme SCD1 catalyzes the 
biosynthesis of major FA in tissue lipids by introducing a double bond to 
0
50
100
150
200
250
300
350
400
450
500
C
1
4
:
0
C
1
6
:
0
C
1
6
:
1
 
(
n
-
9
)
C
1
6
:
1
 
(
n
-
7
)
C
1
8
:
0
C
1
8
:
1
(
n
-
9
)
C
1
8
:
2
(
n
-
6
)
C
1
8
:
3
(
n
-
6
)
C
1
8
:
3
(
n
-
3
)
C
2
0
:
0
C
2
0
:
1
C
2
0
:
2
C
2
0
:
3
(
n
-
3
)
C
2
0
:
4
C
2
2
:
6
F
r
e
e
 
 
f
a
t
t
y
 
 
a
c
i
d
 
c
o
n
.
 
 
(
m
g
/
1
0
0
 
g
 
l
i
v
e
r
)
Free fatty acids in liver
DIO-V
DIO-25058 
palmitic acid (C16:0) and stearic acid (C18:0), converting them into 
palmitoleic acid (C16:1) and oleic acid (C18:1), respectively. In general, the 
C16:1 content in the diet is relatively low and most of the C16:1 is derived 
from endogenous synthesis catalyzed by SCD1. Therefore FA index can be 
used as a surrogate measurement of SCD1 activity and considered as a 
biomarker for de novo lipogenesis in humans as well as rodents (Ntambi, 1999; 
Warensjö et al., 2009).  
In general, SCD18 index (18:1n-9/18:0) reflects FA chain elongation and 
subsequent desaturation (Warensjö et al., 2009; Cedernaes et al., 2013). In this 
thesis, non-significant differences were observed in SCD18 index in DIO-250 
mice compared with the control. Slightly lower activity was observed in liver 
samples of the DIO-250 group, compared with the control. In contrast, 
opposing changes were observed in AT, probably due to high C18:1 content in 
the diet. Despite alterations in the endogenous FA pool through different 
physiological processes, the overall FA composition of the diet is also reflected 
by FA composition in AT in rats (Weber et al., 2002; Oosterveer et al., 2009).  
 
 
Figure 24. Stearoyl-CoA desaturase (SCD)-16 index (C16:1n-7/C16:0) and SCD-18 index 
(C18:1n-9/C18:0) as a measurement of SCD1 activity in plasma, liver and white adipose tissue 
samples of diet induced obese mice (DIO), after 6 weeks treatment with 1,3-dilauroyl-2-lipoyl-sn-
glycerol (diLaLA). Abbreviations: DIO-250, DIO mice treated diLaLA 250 mg/kg body wt. daily; 
DIO-V, control treated only with vehicle. Values are mean±standard error of mean (n = 7). 
SCD1 activity influences fat storage and body weight through its activity in 
lipogenesis. Increased SCD1 activity is associated with obesity and estimated 
SCD1 activity is considered a biomarker for increased adiposity (Flowers & 
Ntambi, 2008; Jeyakumar et al., 2009; Warensjö et al., 2009). Downregulation 
of SCD1 activity has been reported in relation to management of obesity and 
improvement of insulin sensitivity, and thus estimated SCD1 activity can be 
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used to evaluate the efficacy of anti-obesity treatments (Jeyakumar et al., 
2009). 
5.5.4 Effects  on  ȕ-oxidation 
 
The results from RT-qPCR analysis provide preliminary insights how 
treatment with diLaLA induced a weight reducing effect through upregulation 
of key genes involved in ȕ-oxidation of FA in the liver in DIO mice on HFD 
(Figure 25). Although the results from gene expression analysis were not tested 
for statistically significant effect due to limited number of replicates, the results 
measured as fold change clearly showed upregulation of peroxisome 
proliferator activated receptor (PPAR)-Į, FA translocase Cd 36, and carnitine 
palmitoyltransferase (CPT)-1 in DIO-250 mice, compared with the control. 
Upregulation of PPAR-Į can trigger target genes involved in rate limiting steps 
in mitochondrial FA uptake for the FA ȕ-oxidation pathway, such as Cd 36 and 
CPT1 (Burri et al., 2010).  
 
Figure 25. Relative expression of genes analyzed by RT-qPCR in liver samples of DIO-250 (n = 
3; r = 2) presented as fold change, compared with the control DIO-V (n = 2; r = 2). Abbreviations: 
DIO-250, DIO mice treated with 1,3-dilauroyl-2-lipoyl-sn-glycerol (diLaLA) 250 mg/kg body wt. 
daily for 6 weeks; DIO-V, control treated only with vehicle; 33$5Į peroxisome proliferator-
activated receptor alpha; Cd36, fatty acid translocase (cluster of differentLDWLRQ  &37Į 
carnitine palmitoyltransferase 1 alpha, and different isomers of AMPK, adenosine 
monophosphate activated protein kinase. 
At the same time, isoforms of Adenosine monophosphate-activated protein 
kinase (AMPK), -ĮDQG-ȖZHUHalso upregulated whereas -ĮDQG-ȕZHUH
down regulated in liver samples of DIO-250 mice compared with the control 
(Figure 25). AMPK is known as a cellular energy sensor and a key regulator in 
hepatic energy metabolism. Hepatic AMPK can limit anabolic pathways and 
facilitates catabolic pathways to increase ATP production. Activation of 
AMPK increase FA oxidation, reduces hepatic lipogenesis and modulates 
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transcription of genes involved in lipogenesis and mitochondrial biogenesis 
(Viollet et al., 2009). 
The low levels of hepatic FFA and TAG along with reduced SCD1 activity 
observed in diLaLA treated mice showed an overall lipogenic suppression 
effect induced by diLaLA in the liver. According to Dobrzyn et al. (2005) this 
lipogenic suppression via reduced SCD1 activity is supported by enhanced 
expression of AMPK. Their study demonstrated that metabolic changes in 
SCD1-deficient mice (SCD-/-) were due to higher energy expenditure induced 
by AMPK activation (Dobrzyn et al., 2005). The authors further explained that 
activation of AMPK decreases malonyl-CoA levels in the liver, consequently 
stimulating CPT1 activity and increasing )$WUDQVSRUWWRPLWRFKRQGULDIRUȕ-
oxidation. The results in this thesis also show upregulation of AMPK isoform -
ĮDQG-ȖDQG CPT1 in DIO-250 mice compared with the control. However, 
$03.LVRIRUPVĮDQGȕZHUHGRZQUHJXODWHGLQ',2-250 mice compared 
with the control. It has been shown that AMPK-Į is associated with FA 
oxidation mediated by leptin through nervous stimulation via the brain 
(Dobrzyn et al., 2005). According to Kim et al. (2004), the LA mediated anti-
obese effect observed in rodents was due to enhanced expression of AMPK in 
peripheral tissues which was mediated by leptin independent manner. It should 
be noted that, pure LA can reduce plasma FFA and TAG via AMPK dependent 
and independent manner (Park et al., 2008). Moreover, replacing dietary TAG 
by 1,3-DAG in mice also resulted in XSUHJXODWLRQRIHQ]\PHVLQYROYHGLQȕ-
oxidation, such as acyl-CoA oxidase and medium-chain acyl-CoA 
dehydrogenase (Murase et al., 2002). 
5.6 Final  remarks 
 
This thesis demonstrates that the novel designed TAG molecule (diLaLA), a 
conjugate of two naturally existing molecules 1, 3-dilaurin and R-(+)-LA 
significantly reduced body weight and FFA concentration in both plasma and 
liver in DIO mice. These novel derivatives were completely soluble in 
vegetable oil such as rapeseed oil, in room temperature showing relatively 
higher solubility than the initial compounds, which occur as a powder. A 
previous study, which tested 0.3% (wt./wt.) racemic LA mixed with medium 
chain TAG oil in a diet (10% fat) given to hamsters for 4 weeks did not 
observe any effect on body weight (Wollin et al., 2004). The authors suggested 
that their results might be due to low solubility of LA powder in TAG oil, 
probably leading to poor bioavailability. Therefore improved solubility in oils 
is important in potential applications as functional lipids or supplement 61 
because it facilitates uniform blending, consistent composition and 
effectiveness.  
The solubility of novel TAG molecule may also depend on the fatty acids 
esterified in the glycerol backbone. It should be noted that the novel derivative, 
diLaLA investigated for anti-obesity effects in this thesis, constituted of C12:0. 
Naturally 1,3-DAG may constitute of any common fatty acid such as C18:1, as 
it was used to synthesize for the first time, in the beginning of this study (Paper 
II). According to previous research, fatty acid composition of DAG molecule 
would not affect the weight reducing properties associated with 1,3-DAG 
(Murase et al., 2001; Murase et al., 2002). However, fatty acid composition 
may affect the stability of the novel derivative. In addition to the advantage of 
stability, lower cost of production prompted us to continue the study of this 
thesis (Papers III-V), using diLaLA containing, C12:0. 
To our knowledge, there is no naturally occurring TAG molecule which has 
one or more LA molecule/s esterified in its glycerol backbone. The in vitro 
hydrolysis of diLaLA tested as a preliminary screening of intestinal digestion 
mediated by pancreatic lipase showed it can be completely digested, releasing 
monolipoate, C12:0 and LA. However, it should be noted that the conditions 
used in this single-step in vitro experiment were far from actual in vivo 
conditions in the gastrointestinal tract of mice. In live conditions, diLaLA 
might be subjected to acidic pH and other biochemical conditions in the 
stomach, which might result in some prior hydrolysis of the novel TAG 
molecule before digestion by lipase. Considering these factors, the observed 
effects of diLaLA can be due to both 1,3-DAG and LA.  
It should be noted that according to previous studies, 1,3-DAG is required 
in relatively higher amounts (g amounts), replacing dietary TAG to show a 
significant in vivo effect on energy expenditure and reduce fat accumulation, 
compared with pure LA supplemented in relatively small amounts (mg 
amounts). However, which initial constituent in diLaLA molecule caused this 
weight reducing effect at molecular level, is difficult to speculate at this stage 
since we don´t know how this novel TAG molecule is digested in the 
gastrointestinal tract in live animals. Nevertheless, the results from previous 
studies conducted with pure 1,3-DAG and LA separately provide some idea of 
how the observed outcomes could have been mediated by diLaLA. 
Nevertheless, the results presented in this thesis are consistent with previous 
studies, which showed similar effects by dietary supplementation of pure LA in 
rodents (Kim et al., 2004; Park et al., 2008; Prieto-Hontoria et al., 2009; Wang 
et al., 2010). It is of interest to note that Kim et al. (2004) tested dietary 
supplementation of LA at 0.25, 0.5 and 1.0% (wt./wt.) levels corresponding to 
approx. 150, 300 and 600 mg pure LA/kg body wt., respectively. A similar 62 
high dose of LA i.e. 500 mg/kg, was used in C57BL/6J mice treated for four 
weeks by Wang et al. (2010). In contrast, mice studied in this thesis were 
treated with oral doses of diLaLA, which contained only 32% LA based on the 
molecular weight of diLaLA. Thus the doeses at 10, 50 and 250 mg diLaLA/kg 
body wt. tested in this thesis, may correspond to 3, 16 and 80 mg of LA/kg 
body wt., respectively. The results in this thesis, show that diLaLA is effective 
in mediating a significant reduction in body weight and FFA concentration in 
HFD diet induced obese mice. This effect was found at the dose level 250 mg 
diLaLA/kg body wt. which could be probably a relatively low dose level of 
LA, compared with previous studies in rodents treated with pure LA, indicating 
possible synergistic effect of this novel derivative. Probably this indication of 
enhanced effect might be due to 1,3-DAG in addition to LA. It has been shown 
that TAG in the diet replaced by 1,3-DAG, enhanced energy expenditure, 
reduced fatty acid synthesis in liver, fat accumulation and body weight as 
mentioned previously in this thesis (Maki et al., 2002; Murase et al., 2001; 
Murase et al., 2002; Rudowska et al., 2005; Yanai et al., 2010). Further, it 
could also be due to increased solubility and stability of the novel conjugate 
which might have improved bioavailability, as discussed previously. 
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6 Main  findings   
 
x  A mild esterification method to synthesize PS and 1,3-DAG 
derivatives with LA, resulting in approx. 60 and 80% of final products 
with a higher solubility in vegetable oils, than initial compounds. 
 
x  The  in vitro free radical scavenging capacity of novel DHLA 
derivatives of PS and 1,3-DAG were comparable to that of pure 
DHLA, as evaluated by DPPH method under test conditions.  
 
x  Pancreatic lipase mediated in vitro hydrolysis of diLaLA resulted in 
complete digestion, releasing monolipoate, free C12:0, and LA under 
tested conditions. 
 
x  Free LA was detectable in plasma samples of mice 2 h after oral 
treatment with diLaLA.  
 
x  Oral treatment with 250 mg diLaLA/kg body weight daily for 6 
weeks, significantly reduced body weight gain, and plasma and 
hepatic FFA concentrations in DIO mice on HFD. 
 
x  Oral treatment with 250 mg diLaLA/kg body weight daily for 6 weeks 
also lowered the SCD1 activity, estimated by SCD16 index in white 
adipose tissues, while inducing expression of some key genes involved 
LQȕ-oxidation of fatty acids in the liver of DIO mice.  
 
x  The novel derivative, diLaLA reduced body weight in DIO mice 
possibly through enhanced energy expenditure YLD ȕ-oxidation and 
suppressing in vivo lipogenesis, suggesting its potential in alleviating 
some risk factors associated with obesity.  64 
7 Future  research 
x  Phytosterol lipoates need to be investigated for their potential 
cholesterol lowering effects in animals. 
 
x  An  in vivo study is important to monitor the pharmacokinetic and 
pharmacodynamic parameters and evaluate the relative bioavailability 
of orally administered diLaLA.  
 
x  The effects RI GL/D/$ RQ H[SUHVVLRQ RI JHQHV LQYROYHG LQ )$ ȕ-
oxidation and lipogenic enzymes such as SCD1 needs to be further 
investigated.  
 
x  A long term study to evaluate whether diLaLA mediated anti-obesity 
effects are maintained long term.  
 
x  A toxicological study to investigate possible adverse effects of long 
term oral treatment with diLaLA. 
 
x  Identification of possible digestion products of diLaLA in in vivo 
conditions and their metabolites in plasma and urine after oral 
administration would be of interest. 
 
x  Anti-obesity effect of similar LA derivatives with 1,3-DAG, 
containing fatty acids other than C12:0 would also be of interest. 
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